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Abstract
According to the Centers for Disease Control and Prevention (CDC) the prevalence of
obesity in adults in the United States during 2017-2018 was a 42.4%, a high number
considering all the risks factors associated with this disorder, such as cardiovascular disease,
insulin resistance, diabetes type 2, and fatty liver disease, among others. Fatty liver disease is
the accumulation of lipids in the liver that can account for more than 5 to 10% of the liver’s
weight. There are two types of fatty liver disease, alcoholic fatty liver disease (AFLD), and nonalcoholic fatty liver disease (NAFLD). AFLD is the detrimental accumulation of lipids in the liver
due to sustained alcohol consumption. NAFLD is the aggregation of lipids in the hepatocytes
that cannot be explain by alcohol intake. In this study, we analyzed the beneficial impact of
consuming a soy-based diet in ameliorating the effects of NAFLD on obese Zucker rats.
We conducted global gene expression analysis on samples extracted from livers of
Zucker rats that were fed diets containing either soy protein isolate (SPI) or casein (CAS) during
8 (short-term) and 16 weeks (long-term) (Hakkak et al. 2015). In order to validate the
transcriptomics data we run qPCR on some of the most deferentially expressed genes, and
found good correlation between both using a cut off value of 1.3 fold and P < 0.005. There were
several genes either up- or down-regulated in SPI feeding group that are consistent with the
literature. There were also novel findings linking the up regulation of a gene (such as NPTX2)
with SPI and NAFLD that were never reported before to our knowledge. In addition, we used
Ingenuity Pathway Analysis (IPA) software to help us to interpret the data analysis. We
compared the effects of the short-term SPI diet versus long-term on the same diet. The results
seem to indicate that the longer the obese rats were on the SPI diet the more beneficial were its
effects in two main functions we focused on: inflammatory response predicted by IPA to be
inhibited, and lipid metabolism, predicted to be activated in SPI feeding versus the control
group.
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CHAPTER 1
INTRODUCTION
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1.1 Introduction
An important medical condition linked to metabolic syndrome and obesity, nonalcoholic
fatty liver disease (NAFLD) is characterized by mild steatosis, that if left unchecked, leads to
non-alcoholic steatohepatitis (NASH), and finally to cirrhosis if damage continues. NAFLD can
be described as abnormal accumulation of lipids within liver cells not associated with alcohol
consumption. It is commonly accepted that the course of NAFLD takes place in two stages. In
the first stage, insulin resistance develops that is accompanied by lipid accumulation in the liver
in the form of triglycerides. In the second stage, mitochondrial dysfunction with mitochondrial
reactive oxygen species production promotes oxidative stress leading to inflammation and
hepatic fibrosis (Berardis, 2014; Fang, 2018). A revision of the progression of pathogenesis has
been proposed in which NAFLD can be tentatively diagnosed in patients with elevated liver
enzymes and by imaging in the absence of other causes of liver disease. However, a definitive
diagnosis can only be made by liver biopsy (Serviddio et al., 2008; Weiß et al., 2014).
Estimations of the prevalence suggest that NAFLD could be the most common form of chronic
liver disease in adults, and that it may affect 10% to 35% of the worldwide population (Bellentani
and Marino 2009). There is also increasing concern of NAFLD as a significant form of liver
disease in pediatric populations (Berardis and Sokal, 2014; Iranikhah et al., 2018).
Described for the first time in 1988, metabolic syndrome is a condition in which many
metabolic diseases or disorders [e.g., insulin resistance, type 2 diabetes, nonalcoholic fatty liver
disease (dyslipidemia), metabolic fatty liver disease, and obesity] along with vascular disorders
including hypertension, thrombosis, and inflammation may be present in the same patient
(Grundy 2008; Reaven 1988; Weiss et al. 2004). For example, the risk of atherosclerotic
cardiovascular disease is doubled in individuals with metabolic syndrome (Grundy, 2008).
Metabolic syndrome has its roots in obesity related to a sedentary lifestyle, where susceptibility
factors such as adipose tissue disorders and genetic factors are also present as well. In 2016,
the prevalence of obesity in the US was 39.8% in adults and 18.5% in youth (Hales et al., 2017).
2

Feeding SPI diet reduced liver steatosis in male obese Zucker rats compared to those
fed a casein (CAS)-based diet (Hakkak et al., 2015). The exact mechanism responsible for the
amelioration of liver steatosis by dietary SPI is not fully established. The SPI diet specifically
targeted and halted the development of liver steatosis in this obese rat model. Microscopy
analysis of liver tissue clearly showed less liver steatosis in obese rats fed the SPI-based diet
compared to those fed the control CAS-based protein diet (Hakkak et al., 2015). Possibly,
feeding the SPI-based diet may have altered expression of key genes associated with
fundamentally important processes in the development of liver steatosis (e.g., lipid metabolism
or inflammation) that counteracted the underlying genetic proclivity of these genetically obese
rats to develop liver steatosis. Therefore, we have conducted a transcriptomic study to assess
global gene expression in liver tissue obtained from CAS and SPI-fed rats to reveal potential
gene expression signatures that were altered by feeding SPI to obese Zucker rats. The power of
global expression analyses such as RNAseq is that it offers the capability of generating datasets
that are hypothesis free that can lead researchers to discover new mechanisms free of
constraints of hypotheses-driven research. The major goal of the RNAseq study is to identify
new mechanisms that SPI is able to attenuate NAFLD. The first step in doing this is to validate
the RNAseq dataset by comparing expression values to those obtained by RT-PCR. Genes that
were selected for testing were ones that were most differentially expressed in liver obtained
from SPI- and CAS-fed rats that were identified by Ingenuity Pathway Analysis software
(Qiagen, CA). Future studies will utilize pathway analysis to reveal fundamental mechanisms
associated with SPI-attenuation of liver steatosis.
1.2 Objectives
The major goal of the research conducted on this dissertation was to gain insight into
mechanisms by which feeding SPI is able to attenuate liver steatosis in obese Zucker rats
(Hakkak et al. 2015).
Specific objectives are:
3

1) To conduct global gene expression analysis (transcriptomics) on liver tissue obtained by
Hakkak et al. (2015) from genetically obese Zucker rats fed a diet containing SPI versus Casein
for 8 and 16 weeks of treatment.
2) To validate global expression datasets (transcriptomics) by targeted mRNA expression
analysis using reverse transcriptase polymerase chain reaction RT-PCR.
3) To understand liver functions that might be enhanced or inhibited after 16 weeks of SPI
treatment through upstream regulator analysis using Ingenuity Pathway Analysis software
(Qiagen, CA).
4) To compare upstream regulator analysis obtained in global expression after 8 and 16 weeks
of SPI treatment using Ingenuity Pathway Analysis software (Qiagen, CA).
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CHAPTER 2.
LITERATURE REVIEW
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2.1 Metabolic Syndrome, Obesity, and Non-alcoholic Fatty Liver Disease
Described for the first time in 1988, metabolic syndrome is a condition in which many
metabolic diseases or disorders [e.g., insulin resistance, type 2 diabetes, nonalcoholic fatty liver
disease (dyslipidemia), metabolic fatty liver disease, and obesity] along with vascular disorders
including hypertension, thrombosis, and inflammation may be present in the same patient
(Francisco et al., 2019; Grundy, 2008; Reaven, 1988). For example, the risk of atherosclerotic
cardiovascular disease is doubled in individuals with metabolic syndrome (Whaley-Connell et
al., 2011). Metabolic syndrome has its roots in obesity, which nowadays its known to be caused
by insulin resistance and a wide range of physiological imbalances in adipokines and
proinflammatory molecules, with adipose tissue playing a major role as an endocrine organ (Kita
et al., 2019).
An important medical condition linked to metabolic syndrome and obesity, nonalcoholic
fatty liver disease (NAFLD) is characterized by mild steatosis, that might lead to non-alcoholic
steatohepatitis (NASH), and finally to cirrhosis if damage continues. NAFLD can be described
as abnormal accumulation of lipids within liver cells not associated with alcohol consumption.
Traditionally, it has been considered that the course of NAFLD takes place in two stages. In the
first stage, insulin resistance develops that is accompanied by lipid accumulation in the liver in
the form of triglycerides. In the second stage, mitochondrial dysfunction with mitochondrial
reactive oxygen species production promotes oxidative stress leading to inflammation and
hepatic fibrosis (Berardis and Sokal, 2014; Iranikhah et al., 2018). A revision of the progression
of pathogenesis has been proposed in which NAFLD can be tentatively diagnosed in patients
with elevated liver enzymes and by imaging in the absence of other causes of liver disease.
However, a definitive diagnosis can only be made by liver biopsy (Fang et al., 2018; Weiß et al.,
2014). Estimations of the prevalence suggest that NAFLD is one of the most common form of
chronic liver disease in adults in the US, Asia, Australia, and Europe. Moreover, it is estimated
that affects 20–30% of the worldwide population, and that is higher in developed countries
7

(Buzzetti et al., 2016); although the prevalence of the disease has doubled in the US in recent
years (Fang et al., 2018). The predominance of NAFLD in children and adolescents has also
been increasing in the last decades, with an occurrence of twice in boys than in girls (Fang et
al., 2018). According to Iranikhah et al., the prevalence varies between 3% and 80% in children
with normal weight and over-weighted or obese children, respectively (Iranikhah et al., 2018).
Although the exact causes are not well understood, there is consensus that it is the result of a
combination of environmental, individual and genetic factors (Fang et al., 2018; Iranikhah et al.,
2018). For this reason, the “two hits” hypothesis has been replaced by a “multiple-hit”
hypothesis (Buzzetti et al., 2016; Fang et al., 2018). The multiple-hit hypothesis not only
considers hereditary and environmental aspects, but it also acknowledges the importance of
inflammatory pathways, and the gut-liver axis (GLA) dysfunction, that includes an imbalance on
the gut microbiota, also known as intestinal dysbiosis, with modification of intestinal mucosa
permeability to bacteria and or derive endotoxins (Buzzetti et al., 2016; Fang et al., 2018).
Components in the diet can regulate liver steatosis. A high saturated fat diet increases
liver lipids and plasma insulin levels, inducing insulin resistance, and affecting mitochondrial
function. Inflammatory stimuli play a role in the progression of NAFLD to NASH through the
activation of nuclear receptors. Liver cells are involved in many pathways of lipid metabolism
and also according to their location within the lobule (Tessari et al., 2009). Various factors that
contribute to the dysregulation include both modifiable (e.g. obesity, insulin resistance) and nonmodifiable risk factors (age-associated physiologic changes). Although there is no linear
relationship between aging and prevalence of non-alcoholic fatty liver disease, current data
strongly suggests that advanced age leads to more severe histological changes and poorer
clinical outcomes. Hepatic lipid accumulation could lead to significant hepatic and systemic
consequences including steatohepatitis, cirrhosis, impairment of systemic glucose metabolism
and metabolic syndrome, thereby contributing to age-related diseases. Insulin, leptin and
adiponectin are key regulators of the various physiologic processes that regulate hepatic lipid
8

metabolism. Recent advances have expanded our understanding in this field, highlighting the
role of novel mediators such as Fibroblast growth factor (FGF) 21, and mitochondria derived
peptides (Gong et al., 2017; Fang, 2018).
It is known that the development of NAFLD is accompanied by the expression of
proinflammatory and immune response related molecules. Studies have been targeting CD47
for a possible therapeutic treatment in the suppression of tumor growth due to its ability to inhibit
the phagocytosis mediated by macrophages function (Lee et al., 2014).
Another molecule well known by its presence during the progression of NAFLD,
lipocalin-2 (LCN2), an adipokine expressed in neutrophils and involved in innate immunity
(Alwahsh et al., 2014; Auguet et al., 2013; Friedl et al., 1999). Furthermore, the expression of
LCN2 has been found linked to another molecules, Chemokine (C-X-C motif) ligand 9 (CXCL9)
and 16 (CXCL16) (Semba et al., 2013; Tokunaga et al., 2018), cytokines involved in the
induction of chemotaxis, multiplication of leukocytes, and recruitment of immune cells to the
inflammation site (Tokunaga et al., 2018). CXCL9 is also present in patients with NAFLD and
NASH, and it is currently being studied along CXCL10, CXCL11/CXCR3 as a possible target in
cancer therapy (Tokunaga et al., 2018). Pharmacological inhibition of CXCL16 has been tested
successfully in the reduction of macrophage infiltration in hepatic steatosis and hepatic damage,
and therefore, a reduction in inflammation (Wehr et al., 2014).
2.2. Functional Food Components and Non-alcoholic Fatty Liver Disease
There is considerable evidence of the implication of dietary components, such as
isoflavones in soybeans and resveratrol in wine, that can alleviate the symptoms of metabolic
conditions such as liver steatosis; e.g. (Chen et al., 2015). Examples of these include
isoflavones, such as genistein and daidzein, and resveratrol found in red wine.
2.2.1 Genistein
Genistein is one of the most abundant isoflavones in soybean. It has been found that at
the cellular level genistein inhibits cellular cholesterol synthesis and cholesterol esterification in
9

HepG2 human hepatoma cells (Borradaile et al, 2002). Genistein also affects fatty acid
oxidation. It exerts antidiabetic and hypolipidemic effects through the upregulation of the PPARregulated (peroxisome proliferator-activated receptor) gene expression. Thus, the effects of
genistein on cholesterol synthesis and fatty acid oxidation are well known. However, the effect
of genistein on fatty acid synthesis has not yet been identified (Shin et al., 2007). Shin et al,
2007 studied the effect of genistein on fatty acid synthase (FAS) expression. FAS is not a single
protein but an enzymatic system that catalyzes fatty acid synthesis. In humans, FAS is encoded
by the fasn gene. FAS plays a central role in de novo fatty acid synthesis and in the long-term
regulation of lipogenesis (Semenkovich, 1997). In the study mentioned above, the researchers
reported that genistein inhibited S1P expression, which resulted in an inhibition of the SREBP-1
activation process and consequent downregulation of SREBP-1 regulated genes, such as FAS,
SCD1, ACC, and GPAT in HepG2 cells (Shin et al., 2007). Genistein also improves blood
pressure and restores renal function as shown in a high-fructose fed rat model (Palanisamy and
Venkataraman, 2013). These beneficial effects are probably exerted by inhibitory effect on
angiotensin-converting enzyme (ACE) and protein kinase C-bII (PKC-bII) activation. Genistein
has also been reported to enhance adipogenesis through modification of peroxisome
proliferator-activated receptor-γ (PPARγ) (Relic et al., 2009) and canonical Wnt/β-catenin
signaling (Su and Simmen, 2009). Wnt signaling cascade is an important autocrine and
paracrine regulator of adipogenic programming. In addition, the canonical Wnt/β-catenin
pathway inhibits PPARγ and C/EBPα through downstream activation of T cell factor/lymphoid
enhancer factor (TCF/LEF) (Prestwich and MacDougald, 2007). The mechanistic of such
regulation remains unclear (Cain et al., 2011).
2.2.2 Daidzein
Daidzein is the second most common isoflavone in soybean. It has been related to
genistein in many of its properties. A study conducted in obese diabetic Zucker rats in 2003
showed a how daidzein along with genistein could be exerting an antidiabetic role by activating
10

peroxisome-proliferator activator receptors (PPAR) and regulating glucose and lipid metabolism
(Mezei et al., 2003). Daidzein has also been found to inhibit inducible nitric oxide synthase in
activated macrophages, which in turn leads to inhibition of nitric oxide production and therefore
has anti-inflammatory effects (Hämäläinen et al., 2007). It also inhibits the activation of nuclear
factor-κB (NF-κB), a transcription factor of inducible nitric oxide synthase, enhancing its antiinflammatory effect (Hämäläinen et al., 2007). Daidzein has also be found, along with genistein,
to promote apoptosis in cancer colon cells by down-regulating lipid metabolism associated
genes and reducing the accumulation of lipid droplets in these cells (Liang et al., 2018).
2.2.3 Resveratrol
Resveratrol is a natural polyphenol found in grapes, peanuts, berries, and red wine.
Currently, resveratrol is used as a dietary supplement. The acceptable daily intake is 450
mg/day. In vitro, Renes et al. found that, when compared with calorie restriction, resveratrol
treatment was more beneficial in reducing obesity-related metabolic complications and
alleviating the inflammatory phenotype (Renes et al., 2014). Resveratrol can regulate liver lipid
metabolism to prevent the development of NAFLD in animals (Mukherjee et al., 2010). Some
studies conducted in rodent models have shown that resveratrol can inhibit the development of
NAFLD by decreasing the levels of AST, ALT and Apo-B, as well as by decreasing body weight,
blood glucose, triglycerides, total cholesterol, and LDL-cholesterol (Gómez-Zorita et al., 2012;
Shang et al., 2008). In human studies, resveratrol induced SIRT1 expression and improved the
human adipocyte secretome in a manner similar to that of low-glucose calorie restriction.
Timmers et al. observed modest improvements in insulin sensitivity, blood pressure, metabolic
rate, hepatic steatosis, and pertinent biomarkers in healthy obese males after 150 mg/day
resveratrol supplementation (Timmers et al., 2011). Clearly, resveratrol has a variety of
biochemical and physiological effects including the following: anti-oxidative, decreased fatty acid
availability, anti-inflammatory, anti-obesity, improved lipid metabolism, and improved insulin
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sensitivity (Liu et al., 2014). However, the true efficacy and mechanisms of action of resveratrol
in NAFLD are not yet fully understood.
2.3 Effect of Feeding Soy Protein Isolate (SPI)
In 2015, Hakkak et al., compared the effects of short and long term (8 and 16 weeks
respectively) of a SPI-based diet in obese Zucker rats. They were able to demonstrate that SPI
exerts an anti-steatotic effect on the livers of those rats fed exclusively with SPI, and the longer
the treatment the higher the benefits. SPI attenuated the liver steatosis in the Zucker rats
compared with the controls. Hakkak et al., also proved that SPI reduces the levels of markers of
liver damage (elevated ALT levels), and proinflammatory cytokines such as TNF and IL-6
(Hakkak et al., 2015).
It is apparent that liver steatosis was dramatically reduced in liver of obese Zucker rats
fed a diet containing SPI compared to ones receiving a conventional chow. However, the reason
for SPI ability to reduce liver steatosis is not apparent. By learning what effect SPI feeding had
on gene expression in this obese rat model, it may be possible to develop new methods or
treatments that reduce fatty liver disease and halt its progression to irreparable damage seen in
cirrhosis. To this end global expression analysis studies were conducted with results presented
in subsequent chapters (see Chapter 3, 4 and 5). In these studies, several genes and molecules
were revealed to be potentially involved in the mitigation of NAFD. These genes are discussed
below.
2.4 Genes-Molecules of Interest in This Dissertation
In the course of investigating gene expression in studies presented in subsequent
chapters in this dissertation, a number of molecules or genes became ones of interest as they
were revealed to be most differentially expressed or were predicted to be activated or inhibited
in liver of obese rats fed a SPI compared to CAS-based diet. These genes are discussed briefly
below.
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2.4.1 Neuropentraxin 2 (NPTX2)
NPTX2 belongs to the pentraxin family is a member of an ancient superfamily of genes
that is phylogenetically highly conserved across the animal kingdom (Mantovani et al., 2008).
This superfamily can be divided according to their length and mechanisms of action into short
and long pentraxins. Long pentraxins, are cytokine-inducible genes or molecules expressed in
different tissues, including adipocytes, monocytes, and endothelial cells. NPTX2 is a type of
neuronal long pentraxin involved in excitatory synapse formation. Moreover, NPTX2 is known to
be up-regulated in Parkinson’s disease and in pancreatic cancer (Park et al., 2007). The
proteins of the pentraxin family are in a class of pattern recognition receptors (PRRs) and
therefore are involved in acute immunological responses (Gewurz et al., 1995). Pentraxins are
acute phase catalysts interacting with cytokines to modulate inflammation at both tissue and
systemic levels. The plasma concentration of the short pentraxin C-reactive protein, secreted by
the liver, is an approved marker as a diagnostic tool of systemic inflammation in obese
individuals (Barazzoni et al. 2016; Mantovani et al. 2008). However, pentraxin 3 (PTX3), which
is a typical structure for long pentraxins, has been reported to limit tissue damage and the
inflammatory process in several disease models, including atherosclerosis, myocardial
infarction, kidney injury, and experimental carcinogenesis (Barazzoni et al., 2016; Mantovani et
al., 2008). As NAFLD and obesity are associated with a general systemic inflammation due to
elevated circulating levels of proinflammatory cytokines such as tumor necrosis factor α (TNF-α)
and interleukin (IL) 6, the increase in NPTX2 expression in SPI-fed rats might be an intrinsic
mechanism that functions to attenuate systemic inflammation in NAFLD.
In addition, there are epigenetic studies focused on aging that relate several
components found in the diet, such as epigallocatechin-3-gallatte (EGCG) from green tea and
genistein from soybeans, that could be controlling gene expression through DNA methylation
(Johnson et al., 2012). This type of DNA methylation can occur not only on the coding regions of
specific genes of interest, but also on their promoters (Bacalini et al., 2014). In these studies,
13

the gene NPTX2 is indicated as one of the most important genes under epigenetic influence
(Bocklandt et al., 2011), along with tumor suppressor genes such as hMLH1 and RARb
(Bacalini et al. 2014; Johnson et al., 2012).
2.4.2. Interleukin 33 (IL33)
IL33 belongs to the IL1 superfamily of cytokines expressed in healthy vascular
endothelial cells, epithelial cells, fibroblasts and smooth muscle cells (Haraldsen et al., 2009;
Miller, 2011). IL33 is expressed primarily in cells from tissues involved in the production and
maintenance of a barrier. When the barriers are damaged, IL33 behaves as an alarm, being
released and initiating the acute local inflammation and tissue-repair process. IL33 has a
function as a ligand for the Th2-associated ST2 receptor activating NFkB and mitogen-activated
kinases. IL33 also has a function as a nuclear factor; thus, regulating gene transcription (Cayrol
and Girard, 2014; Haraldsen et al., 2009; Martin and Martin, 2016; Miller, 2011). IL33 was
reported to be a regulator of hepatic ischemia and reperfusion injury related with the activation
of NFκB, p38 MAPK, cyclin D1, and Bcl-2 that restricts liver injury and decreases inflammation
promoters in mice (Sakai et al., 2012). In a recent review, Sun et al., reported that IL33 may
serve a protective role in fatty liver disease (Sun et al., 2017). Pejnovic et al., developed an
NAFLD mouse model through feeding a high fat diet. Treating these NAFLD mice fed a high fat
diet with IL-33 ameliorating hepatic steatosis as well as insulin resistance and glucose
intolerance (Pejnovic et al., 2016). Furthermore, treating genetically obese mice with IL33
reduced fat accumulation (adiposity), possibly through induction of Th2-mediated cytokine
production (Miller et al., 2010). Thus, it is possible that the elevation of IL33 in SPI-fed rats
played a role in the reduction of liver steatosis compared to CAS-fed rats in the present study.
There are some studies relating consumption or treatment with phytoestrogens with immune
response, mostly when members of IL1 superfamily are involved, and chronic diseases and
other conditions, such as asthma, inflammatory bowel diseases, and radiation-induced bone
marrow failure (Ha et al., 2013; Martin and Bolling, 2015; Sandoval et al., 2010; Tanaka and
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Takahashi, 2013). Nevertheless, little is known regarding the effects of IL33 in the presence of
phytoestrogens or any isoflavones in NAFLD.
2.4.3 Serine Protease
2.4.3a Protease, serine 32 (PRSS32).
The PRSS32 gene is located in chromosome 10 of Rattus norvegicus and has a biased
expression in liver and uterus (https://www.ncbi.nlm.nih.gov/gene/30297). Tryptase-5 protein in
mouse is encoded by Prss32 gene, which is located on chromosome 17, and corresponds to a
functional trypsin-like serine protease (Wong et al., 2004).
2.4.3b Protease, serine 8 (PRSS8).
PRSS8, also known as prostasin and channel-activating protease 1 (CAP1), is a trypsinlike serine peptidase. PRSS8 was first identified as a secreted prostate gland product (Tong et
al., 2004; Yan et al., 2014). In humans, PRSS8 mRNA expression has been detected in
prostate, liver, salivary gland, kidney, lung, pancreas, colon, bronchus, and in some cells from
the kidney (Chen and Chai, 2012; Yu et al., 2014). Uchimura et al., 2014 reported that
upregulation of PRSS8 protected mice from chronic inflammation by reducing toll-like receptor 4
(TLR4) attachment to the endoplasmic reticulum (Uchimura et al., 2014). Furthermore, downregulation of PRSS8 in mice fed a high fat diet contributed to hepatic insulin resistance and
development of diabetes.
2.4.4 Cytochrome P450 genes
The cytochrome P450 superfamily (CYP) is widely present and prominent in both
prokaryotes and eukaryotes. CYP superfamily is classified in families and subfamilies based on
amino acid sequence affinity (Honkakoski and Negishi, 2000; Xu et al., 2005). Numerous
members of this superfamily are involved in electron transport chain systems, having its name
derived from its absorption peak at 450 nm in the visible spectrum/spectra (Danielson, 2005).
The proteins of this superfamily contain a heme group to oxidize their substrates and function as
mono-oxygenases, playing a major protective role from toxic and oxidative damage in the liver,
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intestine, kidney, and lung (Gonzalez and Gelboin, 1992; Xu et al., 2005). CYPs act in a vast
range of functions from the synthesis and metabolism of fatty acids, steroid hormones,
cholesterol, bile acids, and vitamins to drug metabolism and detoxification from xenobiotics and
therefore, have an important role in both exogenous and endogenous substrate metabolism
(Honkakoski and Negishi, 2000; Xu et al., 2005). In humans, the importance of studying and
understanding CYPs mechanisms lies in drug metabolism and interactions (Danielson, 2005).
Many members of the CYP superfamily are induced in liver after exposure with xenobiotics
(Pavek and Dvorak, 2008), including those present in the diet. Families CYP1, CYP2 and CYP3,
to which our analyzed genes belong, are inside this group induced by xenobiotics (Pavek and
Dvorak, 2008). There is a great abundance of studies involving the interaction between CYPs
and specific dietary components (Hamilton-Reeves et al., 2007; Kishida et al., 2004; Li et al.,
2007; Liu et al., 2016; Ronis, 2016). Current studies indicate that consumption of SPI protects
against cancer by down-regulating the expression of CYP1 family members (Rowlands et al.,
2001). There are also several reports where the expression of CYP3 and CYP4 families was
activated or up-regulated by a SPI-diet (Badger et al., 2008; Li et al., 2009; Mezei et al., 2003;
Ronis et al., 2004). In a recent study, it was demonstrated that although SPI maternal
consumption mitigates serum lipid levels on rat male offspring mainly through the up-regulation
of important CYPs such as CYP3A1, the liver protein CYP2C12 was down-regulated in the SPIfed group compared to the CAS-fed group (Won et al., 2017). This finding coincides with our
results in this study.
2.4.5 Sulfotransferase family 2A Member 1 (SULT2A1)
SULT2A1 is a member of the sulfotransferase family, whose members are divided into
families and subfamilies based on their amino acid sequence (Huang et al., 2010).
Sulfotransferases assist in the metabolism of endogenous compounds and drugs through the
biochemical process of sulfation, transforming these substances into more hydrophilic watersoluble molecules that can be easily eliminated from the organism. These proteins catalyze the
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sulfation of steroids, bile acids, neurotransmitters and thyroid hormones in the liver and adrenal
glands (Yalcin et al., 2013). There are cell membrane bound sulfotransferases and cytosolic
sulfotransferases; SULT2A1 is a cytosolic sulfotransferase (Huang et al., 2010; Nowell and
Falany, 2006). Protective effects of diet, mostly soy derived products, against cancer have been
reported through sulfation of flavonoids and other phenolic compounds by cytosolic
sulfotransferases (Pai et al., 2001). SULT1 and SULT2 enzymes showed N-sulfating activities
for carcinogenic heterocyclic amines. SULT2A1 has been shown to sulfate and thus further
bioactivate the classical hepatic procarcinogen N-hydroxy-2-acetylamino-fluorone (Pai et al.,
2001). The detoxification function of liver is illustrated by SULT2A1, playing a major role in bile
acid homeostasis and protection against their toxic effects. SULT2A1 is also found at minor
levels in jejunum, ileum, cecum and kidney cytosol samples (Prima et al., 2013). Mesia-Vela
and Kauffman (2003) determined that when flavonoids are present in the diet they become
potent inhibitors of sulfotransferases such as SULT1A1 in the liver (Mesía-Vela and Kauffman,
2003). This study also stated that the potency of the inhibition of SULT1A1 by flavonoids could
be related to the number and position of hydroxyl groups present in the molecules of such
proteins, with genistein presenting a higher level of inhibition than daidzein. Nevertheless,
Mesia-Vela and Kauffman (2003) did not find a correspondence between number and position
of hydroxyl groups present in flavonoids to inhibit the sulfotransferase SULT2A1, and the
inhibition is less potent that the one exerted over SULT1A1. Yalcin et al. (2013) reported that
there was a clear decrease in several sulfotransferases in a progression from a healthy normal
liver, to steatosis, to cirrhotic livers resulting from diabetes and alcohol (Yalcin et al., 2013).
2.4.6 Regucalcin (RGN)
RGN is a unique calcium-binding protein that does not contain the EF-hand motif1 of calciumbinding domain (Yamaguchi and Murata, 2013). RGN is an androgen-independent factor that

1

The EF-hand motif is the most common calcium binding motif in proteins (Lewit-Bentley and Rety, 2000. EFhand calcium-binding proteins. Curr Opin Struct Biol, 2000 10:637-43)
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decreases with aging (Ishigami et al., 2004). Since the location of RGN is the nucleus, it is
believed to be implicated in the regulation of gene expression. RGN was originally discovered in
1978 as unique calcium-binding protein that does not contain the EF-hand motif of calciumbinding domain. The gene (rgn) is localized on the X chromosome and is identified in over 15
species. It plays a multifunctional role in cell regulation, maintaining of intracellular calcium
homeostasis and suppressing of signal transduction, translational protein synthesis, nuclear
deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis, proliferation, and apoptosis
in many cell types. RGN may play a pathophysiological role in metabolic disorder. The
expression of RGN is stimulated through the action of insulin in liver cells in vitro and in vivo and
it is decreased in the liver of rats with type I diabetes induced by streptozotocin administration in
vivo. Overexpression of endogenous RGN stimulates glucose utilization and lipid production in
liver cells with glucose supplementation in vitro. RGN can reveal insulin resistance in liver cells
(Yamaguchi and Murata, 2013). Deficiency of RGN induces an impairment of glucose tolerance
and lipid accumulation in the liver of mice in vivo. Ishigami et al. (2004) demonstrated that
hepatocytes from RGN-deficient mice revealed many lipid droplets, and abnormally enlarged
mitochondria and lysosomes (Ishigami et al., 2004). RGN deficiency in mice has a profound
effect on the metabolism of neutral lipids and phospholipids such as phosphatidylethanolamine,
cardiolipin, phosphatidylcholine, phosphatidylserine, and sphingomyelin. Thus, it is likely that
this anomaly in the lipid metabolism might decrease the life span of RGN-deficient mice
(Ishigami et al., 2004). The overexpression of endogenous RGN has been shown to decrease
triglyceride, total cholesterol, and glycogen contents in the liver of rats, inducing hyperlipidemia.
Leptin and adiponectin mRNA expressions in the liver tissues are decreased in RGN transgenic
rats. Decrease in hepatic RGN is usually associated with the development and progression of
NAFLD and fibrosis in human patients. RGN may be a key molecule in lipid metabolic disorder
and type II diabetes (Yamaguchi and Murata, 2013). According to a database search, RGN is a
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unique protein, wholly separate from any other family of proteins and has a domain that
resembles that of bacterial and yeast RNA polymerase (Ishigami et al., 2004).
2.4.7 Regulated Endocrine Specific Protein 18 (Resp18)
Resp18 expression is limited to neuroendocrine tissues and sperm (Bloomquist et al.,
1994; Schiller and Darlington, 1996). However, very little is known about this gene or the protein
that it encodes (Zhang et al., 2007) and even less about its relationship with SPI and NAFLD.
Resp18 shares sequence homology with the luminal region of IA-2, a dense core vesicle (DCV)
transmembrane protein involved in insulin secretion -involved in type I diabetes (Zhang et al.,
2007). Although the human version of this protein is not expressed in liver, according to the
webpage for Resp18 gene on NCBI (Provisional) (https://www.ncbi.nlm.nih.gov/gene/50561)
this gene is expressed in lower concentrations in rat liver, suggesting that it may not be a
functional protein. Zhang et al. (2007) cloned two Resp18 splice variants. Resp18-alpha
encodes a deduced 173-amino acid protein, and Resp18-beta encodes a deduced 228-amino
acid protein (Zhang et al., 2007). Both proteins share significant similarity with IA2. Northern blot
analysis of several human tissues detected strong expression of a 0.8-kb transcript in pancreas
and weak expression of 0.8- and 1.2-kb transcripts in placenta. Western blot analysis detected
Resp18 in mouse pancreas, in mouse and rat insulin-secreting beta cells, and in mouse pituitary
corticotropic cells, but not in mouse fibroblasts or human colon carcinoma or HeLa cells (Zhang
et al., 2007). Immunofluorescence analysis of rat pancreas detected Resp18 in most secretory
islet cells examined, and a similar distribution was found in human pancreas. Immunoelectron
microscopy of rat islets localized Resp18 to dense-core vesicles, endoplasmic reticulum, and
Golgi. Zhang et al. (2007) identified Resp18 orthologs only in mammalian genomes (Zhang et
al., 2007).
2.4.8 Cell death induced DFFA like effector A (Cidea)
Cidea is a member of the CIDE family protein, as well as Cideb and Cidec, and are
mitochondrial lipid-droplet-associated proteins involved in regulation of lipid storage and the
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formation of large LDs in adipocytes and hepatocytes (Tiniakos et al., 2010; Zhou et al., 2012;
Carr and Ahima, 2016). Cidea can induce apoptosis through a caspase-independent pathway
(Zhou et al., 2003; Tiniakos et al., 2010). Cidea is well known to be expressed in white and
brown adipose tissue, and in liver. Moreover, Cidea has been directly related with the
development of NAFLD (Zhou et al., 2003; Tiniakos et al., 2010; Wu et al., 2014). In addition,
knockout mice for Cidea and leptin-deficient mice have shown to be lean and obesity resistant
(Zhou et al., 2003; Tiniakos et al., 2010; Wu et al., 2014). Cidea is also up-reglated in the
presence of insulin (Wang et al., 2010).
2.4.9 Guanine nucleotide-binding protein G(i), α-1 subunit (Gnai1),
Gnai1 encodes the alfa subunit of a Guanine nucleotide-binding protein (G protein). G
proteins are important signal transducers present in all eukaryotes, usually located in the cell
membrane, that communicate signals from many hormones, neurotransmitters, chemokines,
and autocrine and paracrine factors (Neves et al., 2002; Jones and Assmann, 2004). Moreover,
G proteins participate in intricate pathways from cell surface receptors with many effectors
downstream. Almost all G protein pathways either stimulate or inhibit one or more of the
Mitogen-Activated Protein Kinase (MAPK) signaling pathways (Neves et al., 2002). All G
proteins are composed of three subunits, alpha, beta and gamma. In general, G proteins
behave as dimers when signaling, although they are heterotrimers, communicating either
through G alpha subunit or G beta-gamma complex (Neves et al., 2002). However, in the Gi
pathway both portions of the G protein, G-alpha subunit and G-beta-gamma complex, can
transmit signals (Neves et al., 2002). Many G proteins have been found by biochemical
purification after the first four were described (Gs, Gt, Gi, and Go) and their subunits identified
by cDNA cloning (Neves et al., 2002; Simon et al.,1991). Gnai1 can regulate cell proliferation
and differentiation, assist platelet aggregation, and act as receptors in multiple cancers (Nguyen
et al., 2018). Acording to Yao et al., (2012), Gnai1 is significantly down-regulated in
hepatocellular carcinoma (HCC) compared with normal liver (Yao et al., 2012). Gnai1 is
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hypothesized to function as an inhibitor of HCC migration and invasion (cancer invasion), and it
has been hypothesized by Nguyen et al., 2018, that Gnai1 is part of a cell mechanism to impede
tumor growth (Nguyen et al., 2018).
2.4.10. Human immunodeficiency virus type 1 enhancer binding protein 2 (HIVEP2)
HIVEP2 is a zinc finger transcription factor located on the chromosome 1 of Rattus
norvegicus genome, and on chromosome 6 in Homo sapiens (Fujii et al., 2005). HIVEP2
contains a ZAS domain composed of two zinc finger motifs, a stretch of highly acidic amino
acids and a serine/threonine-rich sequence. This protein binds a specific DNA sequence similar
to the κB motif present in the Nuclear Factor-κB, usually found in regulatory regions of different
cellular and viral genes that might be involved in growth, development and metastasis, including
those of SV40, CMV, or HIV1. Moreover, related sequences are also found in the enhancer
elements of various cellular promoters, such as those of the class I MHC, IL2 receptor,
somatostatin receptor II, and interferon-beta genes (Wu, 2002). HIVEP2 gene role has been
related with the regulation of immune responses and cellular proliferation (Fujii et al., 2005).
HIVEP2 mRNA is mostly detected in the brain, heart and immune cells (Campbell and Levitt,
2003; Makino et al., 1994; Ron et al., 1991). HIVEP2 deficient mice have a defect in T cell
development, have reduced white adipose tissue, a deficiency associated to defective Bone
Morphogenetic Protein 2 (BMP) dependent adipogenesis and are also hypersensitive to stress
(Jin et al., 2006; Takagi et al., 2006). HIVEP2 translocates into the nucleus as a consequence of
BMP-2 stimulation (Shukla and Yuspa, 2010). HIVEP2 is considered to have a key role in the
activation and function of NK cells and the development of T cell lymphoma (Yamashita et al.,
2012). Vertebrates have at least three orthologs of HIVEP2, namely HIVEP-1, HIVEP-2 and
HIVEP-3 (Wu, 2002). HIVEP genes encode transcriptional proteins that activate or repress the
transcription of a variety of genes involved in growth, development, and metastasis (Wu, 2002).
Allelic loss on human chromosomal locus of HIVEP3, has been usually reported in a variety of
tumors, including breast cancer, liver cancer, and B cell lymphoma. Moreover, changes in gene
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expression of HIVEP1 and HIVEP2 have been associated with poor prognosis in chronic
lymphocytic leukemia patients. Thus, appropriate expression of the HIVEP proteins might be
required to maintain normal growth (Wu, 2002).
2.4.11 Melanoma-associated antigen E1 (MAGEE1).
The first member of the MAGE superfamily has been described in relation to melanoma
cancer cells in 1991 (Chomez et al. 2001). MAGEE1 is a member of a superfamily of genes that
in humans spans about 60 different types of proteins, and most of their genes are located in a
cluster on the chromosome X (Katsura and Satta 2011). The superfamily, whose members all
encode a MAGE homology domain, is divided in two types, type I and type II. Type I MAGE
family includes MAGE-A, -B, and C; while type II contains MAGE-D, -E, -F, -G, -H, and -L
members (Lian et al. 2018). The expression of MAGE superfamily members is highly involved in
cancer development and progression as well as normal functions in embryonic structures and
somatic and stem cells differentiation (Gordeeva et al. 2019). However, their functions remain
unknown.
2.4.12. Short-chain dehydrogenase/reductase family 16C member 6 (Sdr16c6)
Sdr16c6 belongs to the short-chain dehydrogenases/reductases (SDR) superfamily, an
ancient superfamily of enzymes spanning all domains of life, whose members consist of
NAD(P)(H)-dependent oxidoreductases (Kallberg et al., 2010; Kavanagh et al., 2008). Although
its members share sequence motifs and similar mechanisms, sequence identities are low
(Kallberg et al., 2010; Kavanagh et al., 2008). The human ortholog of Sdr16c6 is a pseudogene
(Adams et al., 2017; Kedishvili, 2016). SDRs have a role in the metabolism of lipids, hormones,
prostaglandins, carbohydrates, amino acids, retinoic acid, and xenobiotics, among others. They
also participate in redox sensor systems (Kavanagh et al., 2008; Persson et al., 2009). All SDRs
have in common a Rossmann-fold domain2 and their capacity to bind NAD(P) dinucleotides

2

From https://proteopedia.org/wiki/index.php/Rossmann_fold. The Rossmann fold is a super-secondary structure
characterized by an alternating motif of beta-strand-alpha helix-beta strand secondary structures called a 
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(Kavanagh et al., 2008; Persson and Kallberg, 2013). The retinol dehydrogenase Rdhe2,
homologous to Sdr16c5 and Sdr16c6, has an important role in frog embryonic development
(Belyaeva et al., 2012). In the annotated genome of the amphibian Xenopus tropicalis there is
one gene (rdhe2) homologous to the human version of Sdr16c5 and Sdr16c6, which encode
Retinol Dehydrogenase Epidermal 2 (RDHE2 or Sdr16c5) and Retinol Dehydrogenase
Epidermal 2-Similar (RDHE2S or Sdr16c6) respectively. These genes appeared to have been
recently originated by a duplication event (Belyaeva et al., 2015). According to Belyaeva et al.
(2012) the product of Sdr16c6 gene still has not been characterized in any species (Belyaeva et
al., 2012). However, it seems logical to expect it could be displaying a similar function than
Sdr16c5 in the metabolism of retinoic acid (Belyaeva et al., 2012). Sdr16c6 is one of the genes
affected by vitamin D supplementation in an animal model for Intrahepatic cholangiocarcinoma
(ICC), an aggressive cancer (Chiang et al., 2014). It has a primarily found in liver, lung and
muscle in rat and located in chromosome 5 (https://www.ncbi.nlm.nih.gov/gene/502939#gene-

expression). In Rattus norvegicus, it is predicted to localize to the lipid droplet
(https://rgd.mcw.edu/rgdweb /report/gene/main.html?id=1562060). According to NCBI, is highly
expressed in rat liver at 21 weeks of age (https://www.ncbi.nlm.nih.gov/gene/502939).
2.4.12 Histidine Ammonia Lyase (histidase – HAL).
HAL catalyzes the first reaction in the histidine degradation pathway. HAL is a
cytoplasmic enzyme present in liver and skin tissue and catalyzes the oxidative deamination of
L-histidine to produce urocanic acid and ammonia (Tovar et al., 2002). At the transcriptional
level, HAL is regulated in the liver by the protein content in the diet. The amounts of most amino
acid-degrading enzymes in the liver increase as protein intake rises and decrease as protein
intake falls (Torres et al., 1998). When the histidine requirement has been met, increased HAL

fold. The beta strands participate in the formation of a beta-sheet. The  fold structure is commonly observed
in enzymes that have dinucleotide coenzymes such as FAD, NAD, and NADP.
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expression and activity enables the liver to catabolize and eliminate excess histidine after the
ingestion of a high protein diet. Thus, regulating the histidine concentration in plasma by
controlling the food consumption of histidine is an important role that HAL plays at the cellular
and organismal level (Torres et al., 1998; Tovar et al., 2002). It was determined that both casein
and soy increase hepatic HAL levels (Tovar et al., 2002). However, the groups of rats with
higher intake of both proteins (casein or soy at 50% versus 18%) triggered higher levels of HAL
than the groups with lower intake of the same two protein sources (Tovar et al., 2002). Gene
expression of HAL has been reported to be regulated by estrogen, glucagon, and
glucocorticoids generated during a catabolic state (Armstrong and Feigelsong, 1980; Tovar et
al., 2002). It has been demonstrated that the administration of glucagon to rats promoted the
expression of HAL (Alemán et al., 1998).
2.4.13 Glutamate pyruvate transaminase (GPT)
GPT, also known as alanine aminotransferase, plays a key role in the intermediary
metabolism of glucose and amino acids. Specifically, it is an enzyme that catalyzes the
reversible transamination between alanine and 2-oxoglutarate to form pyruvate and glutamate.
Thus, GPT plays an important role in gluconeogenesis and amino acid metabolism (Jadaho et
al., 2004). Serum activity levels of this enzyme are routinely used as a biomarker of liver injury
caused by drug toxicity, infection, alcohol, and steatosis. Although elevated GPT is considered a
biomarker of NAFLD, caused in part by insulin resistance characteristic of metabolic syndrome
(Calcaterra et al., 2011), this hypothesis has been challenged due to the difficulty in establishing
a direct correlation between the circulating GPT levels and the exact stage of the NAFLD.
Despite the fact that GPT exists as two isoforms (GPT1 and GPT2, respectively) coded by two
different genes located on different chromosomes in humans, the enzymatic activity in
circulation is measured as total GPT (Sookoian et al., 2016). It is also known that both isoforms
not only have different expression pattern in other tissues, but also different intracellular
localizations. According to a recent study (Sookoian et al., 2016), since GPT2 is the
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mitochondrial isoform of this enzyme, circulating levels of GPT should be considered as sensors
of global metabolic deregulation, including mitochondrial energetic control, rather than as merely
a biomarker.
2.4.14 Indolethylamine N-methyltransferase (INMT)
INMT catalyzes the N-methylation of indoles such as tryptamine and related compounds
and a major mechanism for degradation of endogenous and exogenous compounds (Thompson
et al., 1999). However, the function of INMT and the physiological significance of the Nmethylation pathway of indolethylamine metabolism is still not clear (Kärkkäinen et al., 2005;
Thompson et al., 1999). The expression of INMT mRNA has been found in several mammalian
tissues with the highest expression in the thyroid, adrenal gland, and lungs; very low or absent
expression has been reported in brain, spleen, thymus, peripheral blood leukocytes, liver, and
kidney (Thompson et al., 1999). It is also present in most of stromal and epithelial cells of
organs related to the autonomous nervous system but absent from neurons and striated muscle
cells (Kärkkäinen et al., 2005). INMT was indicated to be present in a fatty liver gene set as part
of the human phenotype ontology project (Köhler et al., 2014), but what role it plays in fatty liver
disease is not apparent at this time.
2.4.15 Serpin family A member 6 (SerpinA6)
SerpinA6 belongs to the broadly distributed family of protease inhibitors called serpins.
Serpin-like genes have been described in numerous phyla, from viruses to animals (Law et al.,
2006). Most serpins inhibit serine proteases, but there are some rare serpins performing a noninhibitory function., SerpinA6 which encodes an alpha-globulin also called corticosteroid-binding
globulin (CBG) or transcortin, is primarily produced in the liver and to a lesser extent in the
placenta, kidney, endometrium, lung, pituitary, and hypothalamus (Gagliardi et al., 2010;
Hammond et al., 1987; Law et al., 2006). SerpinA6 is a transporter of several anti-inflammatory
steroids and progesterone in plasma (Henley and Lightman, 2011). Under normal conditions in
humans, about 80% to 90% of cortisol is bound to SerpinA6 with high affinity (Gagliardi et al.,
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2010; Hammond et al., 1987; Richard et al., 2010). By regulating the free cortisol concentration
in blood, SerpinA 6 controls the bioavailability of corticosteroids, thus acting as a buffer during a
secretory surge that can increase the levels of cortisol or as a reservoir of this corticosteroid
during periods of decreased secretion (Gagliardi et al., 2010; Henley and Lightman, 2011).
SerpinA6 levels in blood are associated with body mass index, insulin resistance, serum levels
of interleukin-6, and adiponectin as well as proliferation and differentiation of preadipocytes
(Braun et al., 2010). The role of SerpinA6 as a simple transporter is starting to change in the last
few years. SerpinA 6 is the substrate of elastase that is released in high concentration by
activated neutrophils at sites of inflammation. Once elastase cleaves SerpinA 6, the binding
affinity for cortisol is reduced 10-fold, releasing cortisol at the inflammation site as a result. Thus,
SerpinA 6 might have a key role in preventing tissue damage at inflammatory sites, such as that
occurring in NAFLD, since cortisol modulates inflammatory response (Braun et al., 2010;
Gagliardi et al., 2010).
2.4.16 Ajuba LIM Protein (AJUBA).
AJUBA belongs to the LIM protein family, that is characterized by tandem homologous
C-terminal LIM domains and a unique N-terminal preLIM region rich in glycine and proline
residues (Fan et al., 2015). This arrangement contributes to the linking and/or strengthening of
epithelial cell-cell junctions in part by linking adhesive receptors to the actin cytoskeleton. The
LIM motif is a double zinc finger structure and functions as a protein-protein interface (Fan et al.,
2015). In humans, AJUBA expression was elevated in patients exhibiting nonalcoholic
steatohepatitis (NASH) compared to patients with healthy liver, but there were no differences in
expression between patients with NAFLD compared to those with healthy liver (Arendt et al.,
2015).
2.4.17 Colony stimulating factor 2 receptor subunit beta (CSF2RB)
The CSF2RB protein is the common beta chain subunit of the high affinity receptor for
Interleukin 3 (IL3), IL5, and granulocyte-macrophage colony-stimulating factor receptor (GM26

CSF receptor); these are all cytokines and important regulators of hematopoiesis and
inflammation (Akdis et al., 2011; Woodcock et al., 1994). Tallino et al. (2015) reported that a
copper deficient diet up-regulated CSF2RB in a NAFLD mature rat model (Tallino et al., 2015).
2.4.18. Tumor necrosis factor receptor superfamily member 12A (TNFRSF12A).
TNFRSF12A is a transmembrane protein that causes a weak induction of apoptosis in
some cell types. The human TNFRSF12A gene is expressed at relatively low levels in normal
liver tissue but at high levels in liver cancer cell lines and in hepatocellular carcinoma specimens
(Feng et al., 2000) and the expression of this protein increases in human liver tissue exhibiting
NAFLD (Jakubowski et al., 2005; Wiley et al., 2001). TNFRSF12A promotes angiogenesis and
the proliferation of endothelial cells and modulates cellular adhesion to matrix proteins and
inhibits growth and migration in vitro (Feng et al., 2000). Nuclear factor of activated T-cells 1
(NFAT1), a type of transcription factor, regulates the expression of TNFRSF12A and its ligand,
tumor necrosis factor-like weak inducer of apoptosis (TWEAK), with Lipocalin 2 to increase
breast cancer cell invasion (Gaudineau et al., 2012).
2.4.19 Lipocalin-2 (LCN2)
This molecule belongs to the heterogeneous lipocalin (LCN) family whose members
display differences at the sequence level but remain similar at the structural level (Flower,
1996). The LCN family is involved in the transport of small hydrophobic molecules and other
various functions (Borkham-Kamphorst et al., 2013). LCN2 is a secretory glycoprotein, with
different functions ranging from transport of small molecules such as fatty acids, steroids,
thyroid hormone, and retinoids, to a key role in the innate immunity, iron trafficking, and
induction of apoptosis (Auguet et al., 2011; Flower, 1996). LCN2 is considered an adipocytokine
(Alwahsh et al., 2014; Auguet et al., 2013) and reported to be secreted as a cytokine from the
liver and kidney as well as from neutrophils, and macrophages (Esteve et al., 2009; Wang et al.,
2007). Cell-based immunohistochemistry studies affirm that the main source of LCN2 in liver are
the injured hepatocytes themselves (Borkham-Kamphorst et al., 2013). The presence of LCN2
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protein in blood and urine is an early biomarker of acute kidney injury and other pathologic
conditions (Asimakopoulou et al., 2014; Borkham-Kamphorst et al., 2013; Makris et al., 2012). It
was reported that LCN2 is likely to be one of the adipokines implicated in the pathogenesis of
NAFLD since it is secreted from both adipose tissue and the liver (Auguet et al., 2013). In a dietinducible fatty liver rat model, the researchers found a strong correlation between a high calorie
diet and an increase or up-regulation of hepatic LCN2, elevated indicators of apoptosis,
mitochondrial dysfunction, and lipid peroxidation in the hepatic cells (Alwahsh et al., 2014).
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ABSTRACT
Previously, we reported that feeding soy protein isolate (SPI) reduced liver steatosis in
obese rats compared to those fed a casein (CAS)-based diet; however, the mechanism for this
protection is unknown. To gain insight into the ability of SPI to ameliorate liver steatosis, we
conducted transcriptomic (RNAseq) analysis on liver samples from obese rats fed either the
SPI- or CAS-based diets (n=8 per group) for 8 weeks using an Ilumina HiSeq with 100 base
paired end reads for sequencing. Data were analyzed by Ingenuity Pathway Analysis (IPA)
software using a P < 0.05 and 1.3-fold differential expression cutoff values between the SPIand CAS-based groups. To independently validate the RNAseq data, we conducted targeted
mRNA expression analysis using quantitative PCR (qPCR) on a subset of differently expressed
genes. The results indicate that mRNA expression by qPCR concurred with RNAseq for
NPTX2, GPT, INMT, and HAL that were up-regulated in SPI-fed rats (P < 0.05) and PRSS8,
AJUBA, CSF2RB, and Cyp2c12 that were down-regulated (P < 0.05) in SPI-fed rats compared
to CAS-fed rats. Our findings may shed light on understanding mechanisms enabling SPI diet
to reduce liver steatosis in this obese Zucker rat model.

Key words: obesity, non-alcoholic fatty liver disease, soy protein, gene expression
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INTRODUCTION
Described for the first time in 1988, metabolic syndrome is a condition in which many
metabolic diseases or disorders [e.g., insulin resistance, type 2 diabetes, nonalcoholic fatty liver
disease (dyslipidemia), metabolic fatty liver disease, and obesity] along with vascular disorders
including hypertension, thrombosis, and inflammation may be present in the same patient
(Grundy 2008; Reaven 1988; Weiss et al. 2004). For example, the risk of atherosclerotic
cardiovascular disease is doubled in individuals with metabolic syndrome (Grundy 2008).
Metabolic syndrome has its roots in obesity related to a sedentary lifestyle, where susceptibility
factors such as adipose tissue disorders and genetic factors are also present as well. In 2016,
the prevalence of obesity in the US was 39.8% in adults and 18.5% in youth (Hales et al. 2017).
An important medical condition linked to metabolic syndrome and obesity, nonalcoholic fatty
liver disease (NAFLD) is characterized by mild steatosis, that if left unchecked, leads to nonalcoholic steatohepatitis (NASH), and finally to cirrhosis if damage continues. NAFLD can be
described as abnormal accumulation of lipids within liver cells not associated with alcohol
consumption. The course of NAFLD takes place in two stages. In the first stage, insulin
resistance develops that is accompanied by lipid accumulation in the liver in the form of
triglycerides. In the second stage, mitochondrial dysfunction with mitochondrial reactive oxygen
species production promotes oxidative stress leading to inflammation and hepatic fibrosis (Day
and James, 1998; Masterton et al., 2010). Recently, a revision of the progression of
pathogenesis has been proposed in which NAFLD can be tentatively diagnosed in patients with
elevated liver enzymes and by imaging in the absence of other causes of liver disease.
However, a definitive diagnosis can only be made by liver biopsy (Serviddio et al., 2008; Weiß et
al., 2014). Estimations of the prevalence suggest that NAFLD could be the most common form
of chronic liver disease in adults in the US, Asia, Australia, and Europe that may affect 10% to
35% of the worldwide population (Bellentani and Marino 2009). There is also increasing concern
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of NAFLD as a significant form of liver disease in pediatric populations (Cornier et al. 2008;
Kleiner et al. 2005).
Feeding SPI diet reduced liver steatosis in male obese Zucker rats compared to those fed a
casein (CAS)-based diet (Hakkak et al. 2015). The exact mechanism responsible for the
amelioration of liver steatosis by dietary SPI is not fully established. The SPI diet specifically
targeted and halted the development of liver steatosis in this obese rat model. Microscopy
analysis of liver tissue clearly showed less liver steatosis in obese rats fed the SPI-based diet
compared to those fed the control CAS-based protein diet (Figure 1) (Hakkak et al. 2015).
Possibly, feeding the SPI-based diet may have altered expression of key genes associated with
fundamentally important processes in the development of liver steatosis (e.g., lipid metabolism
or inflammation) that counteracted the underlying genetic proclivity of these genetically obese
rats to develop liver steatosis. Therefore, we have conducted a transcriptomic study to assess
global gene expression in liver tissue obtained from CAS and SPI-fed rats to reveal potential
gene expression signatures that were altered by feeding SPI to obese Zucker rats. The power of
global expression analyses such as RNAseq is that it offers the capability of generating datasets
that are hypothesis free that can lead researchers to discover new mechanisms free of
constraints of hypotheses-driven research. The major goal of the RNAseq study is to identify
new mechanisms that SPI is able to attenuate NAFLD. The first step in doing this is to validate
the RNAseq dataset by comparing expression values to those obtained by RT-PCR. Genes that
were selected for testing were ones that were most differentially expressed in liver obtained
from SPI- and CAS-fed rats that were identified by Ingenuity Pathway Analysis software
(Qiagen, CA). Future studies will utilize pathway analysis to reveal fundamental mechanisms
associated with SPI-attenuation of liver steatosis.
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MATERIALS AND METHODS
Animal Procedures and Diets
All animal protocols were approved by the Institutional Animal Care and Use Committee at
the University of Arkansas for Medical Sciences (Protocol code number 3242; approved on
12/6/2011). Liver tissue was obtained from male obese Zucker rats from a previous study
(Hakkak et al. 2015). Briefly, rats (6 weeks old) were purchased from Harlan Laboratories
(Indianapolis, IN). After one week of acclimation, rats were randomly assigned to either a casein
(CAS) diet or soy protein isolate (SPI) diet. They were housed in individual cages and provided
the diets ad libitum for 8 weeks. At 15 weeks, the rats were humanely killed, and liver samples
obtained, and flash frozen in liquid nitrogen and stored at −80°C.
Transcriptomic Analysis
RNA was extracted from liver samples using phenol chloroform. One percent agarose gel
electrophoresis was used to evaluate the quality of RNA and concentrations were assessed with
Take 3 micro volume plate utilizing Synergy HT multi-mode microplate reader (BioTek,
Winooski, VT). The RNA samples were sent for sequencing to the Research Support Facility at
Michigan State University (East Lansing, MI). Illumina HiSeq 100 base pair paired end read was
used for global expression analysis by RNA sequencing (RNAseq). To map the reads to Rattus
rattus genome assembly version 4, we used CLC Genomics Workbench 8 software that adopts
the pipeline recommended by Mortazavi et al. (Mortazavi et al. 2008). The RPM data was
transformed using log2 to stabilize the variance and then performed a further quantile
normalization. Approximately ~1300 transcripts were differentially expressed (> 1.3 fold
difference and P < 0.05). The software Ingenuity Pathway Analysis (IPA, Qiagen) was used to
help in the interpretation of the dataset.
Real time quantitative PCR (RT-qPCR)
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To validate transcriptomic analysis, targeted gene expression was conducted using RTqPCR). Briefly, RNA was first extracted from liver samples using Trizol reagent (#15596018, Life
Technologies) following the manufacture’s recommendations, treated with DNAase, and reverse
transcribed (catalog #95048-100, Quanta Biosciences). Next, the cDNA (RT products) were
amplified by RT-qPCR (Applied Biosystems 7500 Real-Time PCR system) with Power SYBR
green Master Mix (catalog #4312074, Life Technologies). Primers used in this study, including
the 18S ribosomal housekeeping gene, are shown in Table 1. The cycling conditions for the RTqPCR were as follows: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of a two-step
amplification program with 95°C for 15 s and 58°C for 1 min. To exclude contamination with
unspecific PCR products we used melting curve analysis applying the dissociation protocol from
the Sequence Detection system. The 2–ΔΔCt method was chosen to establish the relative
expressions of target genes in this study (Schmittgen and Livak 2008). Relative mRNA
expression was obtained by normalizing CAS expression values to 1.0 for comparison with the
SPI group.
Statistical evaluation
The analysis of the data was assessed with the software Graph Pad Prism version 6.00 for
Windows, La Jolla California USA, and Student’s t-test. Differences were considered significant
at P<0.05.
RESULTS
RNAseq data
To validate the RNAseq dataset, RT-qPCR was conducted on 12 of the most differentially
expressed genes provided by Ingenuity Pathway Analysis (IPA) in the RNAseq dataset. Fold
differences in mRNA expression by RNAseq and RT-PCR for top up- and down-regulated genes
in liver of the SPI-fed rats compared to CAS-fed rats are shown in Table 2. Regression analysis
of mean values shown in Figure 2 indicate a reasonable agreement and validation of the
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RNAseq dataset based on the correlation coefficient and P value obtained by RT-PCR and
RNAseq. Removal of the one gene (PRSS8, Table 2) that exhibited the greatest difference
between the two gene expression values increased the level of significance of the correlation
(P=0.0003) but had no effect on the correlation coefficient (data not shown). Therefore, we feel
that the data presented in Table 1 represents a viable validation of the RNAseq dataset.
RT-qPCR gene expression
The RT-qPCR analysis of mRNA expression of select genes in this study shown in Figure 3
indicate that 8 of the 12 genes selected based on RNAseq data were differentially expressed
between the CAS and SPI-fed groups. Four genes that were up-regulated in the SPI group were
neuronal pentraxin 2 (NPTX2), glutamic-pyruvic transaminase (GPT), indolethylamine Nmethyltransferase (INMT), and histamine ammonia-lyase (HAL). There were also four genes upregulated in the CAS-fed rats: protease serine 8 (PRSS8), Ajuba LIM protein (AJUBA), colony
stimulating factor 2 receptor beta (CSF2RB), and cytochrome P450 family 2 subfamily c
polypeptide 12 (Cyp2c12). Although tumor necrosis factor receptor superfamily 12A
(TNFRSF12A) and Lipocalin 2 (LCN2) did not show differences between groups by qPCR,
these were differentially expressed in the RNAseq data based on P value and fold difference
cutoffs that had been established (see Table 2). Importantly, the direction of their expression,
either up- or down-regulated, followed the results of the RNAseq analysis.
DISCUSSION
Feeding SPI can attenuate the development of liver steatosis in an obese rat model but the
exact mechanisms responsible for this attenuation are not clear (Hakkak et al. 2015).
Understanding what enables SPI to attenuate liver steatosis could lead to new treatments that
could help control the progression of irreversible damage associated with cirrhosis. To
investigate fundamental mechanisms of SPI-mediated attenuation of NAFLD, we have carried
out global gene expression analysis on liver obtained from obese Zucker rats fed a CAS- or
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SPI-based protein diet. A necessary first step in conducting pathway analysis of global
expression data is to first validate the data by comparison to targeted gene expression analysis
by PCR and is the major goal of the present study. In this study, we have selected genes that
were indicated to be the most differentially expressed (up- or down-regulated) in RNAseq data
obtained from rats fed CAS- or SPI-based diets. In the discussion below, differential expression
of some genes is expected and associated with inflammation that is characteristic of liver
steatosis but expression of other genes (e.g., NPTX2) are novel and have not been reported
previously to our knowledge with respect to NAFLS or soy-based diets.
NPTX2 was up-regulated in the liver of SPI-fed rats (Table 1). NPTX2 belongs to the
pentraxin family is a member of an ancient superfamily of genes that is phylogenetically highly
conserved across the animal kingdom (Mantovani et al. 2008). This superfamily can be divided
according to their length and mechanisms of action into short and long pentraxins. Long
pentraxins, are cytokine-inducible genes or molecules expressed in different tissues, including
adipocytes, monocytes, and endothelial cells. NPTX2 is a type of neuronal long pentraxin
involved in excitatory synapse formation. Moreover, NPTX2 is known to be up-regulated in
Parkinson’s disease and in pancreatic cancer (Park et al. 2007). The proteins of the pentraxin
family are in a class of pattern recognition receptors (PRRs) and therefore are involved in acute
immunological responses (Gewurz et al. 1995). Pentraxins are acute phase catalysts interacting
with cytokines to modulate inflammation at both tissue and systemic levels. The plasma
concentration of the short pentraxin C-reactive protein, secreted by the liver, is an approved
marker as a diagnostic tool of systemic inflammation in obese individuals (Barazzoni et al. 2016;
Mantovani et al. 2008). However, pentraxin 3 (PTX3), which is a typical structure for long
pentraxins, has been reported to limit tissue damage and the inflammatory process in several
disease models, including atherosclerosis, myocardial infarction, kidney injury, and experimental
carcinogenesis (Barazzoni et al. 2016; Mantovani et al. 2008). As NAFLD and obesity are
associated with a general systemic inflammation due to elevated circulating levels of
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proinflammatory cytokines such as tumor necrosis factor α (TNF-α) and interleukin (IL) 6, the
increase in NPTX2 expression in SPI-fed rats might be an intrinsic mechanism that functions to
attenuate systemic inflammation in NAFLD.
In addition, there are epigenetic studies focused on aging that relate several components
found in the diet, such as epigallocatechin-3-gallatte (EGCG) from green tea and genistein from
soybeans, that could be controlling gene expression through DNA methylation (Johnson et al.
2012). This type of DNA methylation can occur not only on the coding regions of specific genes
of interest, but also on their promoters (Bacalini et al. 2014). In these studies, the gene NPTX2
is indicated as one of the most important genes under epigenetic influence (Bocklandt et al.
2011), along with tumor suppressor genes such as hMLH1 and RARb (Bacalini et al. 2014;
Johnson et al. 2012). Thus, it is reasonable to hypothesize that SPI in the present study might
be exerting epigenetic control over NPTX2 expression.
O’Brien et al. (O’Brien et al. 1999) reported that NPTX2 [Narp] protein expression does not
occur in rat liver, yet with our study, we have detected its expression both by PCR and RNAseq.
The team in the aforementioned research (O’Brien et al. 1999) could have obtained a negative
result due to antibody not recognizing the appropriate epitopes for NPTX2. However, it was also
reported that expression of human NPTX2 mRNA does not occur in human liver (Maffei et al.
2004). Thus, the observation of increased NPTX2 expression in SPI-fed rats may be a novel
discovery in the present study.
GPT (or alanine amino transaminase) was also upregulated in the SPI-fed rat liver (Table
1). GPT plays a key role in the intermediary metabolism of glucose and amino acids.
Specifically, it is an enzyme that catalyzes the reversible transamination between alanine and 2oxoglutarate to form pyruvate and glutamate. Thus, GPT plays an important role in
gluconeogenesis and amino acid metabolism (Figure 4) (Jadaho et al. 2004). Serum activity
levels of this enzyme are routinely used as a biomarker of liver injury caused by drug toxicity,
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infection, alcohol, and steatosis. Although elevated GPT is considered a biomarker of NAFLD,
caused in part by insulin resistance characteristic of metabolic syndrome (Calcaterra et al.
2011), this hypothesis has been challenged due to the difficulty in establishing a direct
correlation between the circulating GPT levels and the exact stage of the NAFLD. Despite the
fact that GPT exists as two isoforms (GPT1 and GPT2, respectively) coded by two different
genes located on different chromosomes in humans, the enzymatic activity in circulation is
measured as total GPT (Sookoian et al. 2016). It is also known that both isoforms not only have
different expression pattern in other tissues, but also different intracellular localizations.
According to a recent study (Sookoian et al. 2016), since GPT2 is the mitochondrial isoform of
this enzyme, circulating levels of GPT should be considered as sensors of global metabolic
deregulation, including mitochondrial energetic control, rather than as merely a biomarker.
INMT catalyzes the N-methylation of indoles such as tryptamine and related compounds
and a major mechanism for degradation of endogenous and exogenous compounds (Thompson
et al. 1999). However, the function of INMT and the physiological significance of the Nmethylation pathway of indolethylamine metabolism is still not clear (Kärkkäinen et al. 2005;
Thompson et al. 1999). The expression of INMT mRNA has been found in several mammalian
tissues, having the highest expression in the thyroid, adrenal gland, and lungs. Low or absent
expression has been reported in brain, spleen, thymus, peripheral blood leukocytes, liver, and
kidney (Thompson et al. 1999). It is also present in most of stromal and epithelial cells of organs
related to the autonomous nervous system but absent from neurons and striated muscle cells
(Kärkkäinen et al. 2005). INMT was indicated to be present in a fatty liver gene set as part of
the human phenotype ontology project (Köhler et al. 2014), but what role it plays in fatty liver
disease is not apparent at this time. The up-regulation of INMT in SPI-fed rats could indicate it
has a role in attenuation of NAFLD.
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Histidine ammonia lyase (HAL), also known as histidase, catalyzes the first reaction in the
histidine degradation pathway. HAL is a cytoplasmic enzyme present in liver and skin tissue and
catalyzes the oxidative deamination of L-histidine to produce urocanic acid and ammonia (Tovar
et al. 2002). At the transcriptional level, HAL is regulated in the liver by the protein content in the
diet. The amounts of most amino acid-degrading enzymes in the liver increase as protein intake
rises and decrease as protein intake falls (Torres et al. 1998). When the histidine requirement
has been met, increased HAL expression and activity enables the liver to catabolize and
eliminate excess histidine after the ingestion of a high protein diet. Thus, regulating the histidine
concentration in plasma by controlling the food consumption of histidine is an important role that
HAL plays at the cellular and organismal level (Torres et al. 1998; Tovar et al. 2002). It was
determined that both casein and soy increase hepatic HAL levels (Tovar et al. 2002). However,
the groups of rats with higher intake of both proteins (casein or soy at 50% versus 18%)
triggered higher levels of HAL than the groups with lower intake of the same two protein sources
(Tovar et al. 2002). Gene expression of HAL has been reported to be regulated by estrogen,
glucagon, and glucocorticoids generated during a catabolic state (Armstrong and Feigelsong
1980; Tovar et al. 2002). It has been demonstrated that the administration of glucagon to rats
promoted the expression of HAL (Alemán et al. 1998). To our knowledge, the present study is
the first to report relationships of HAL expression associated with NAFLD in SPI- and CAS-fed
obese Zucker rats.
Four genes in the present study, SerpinA 6, IL-33, TNFRSF12A, and LCN2 were
differentially expressed in the RNAseq data, but were not in the RT-qPCR data (Table 2, Figure
2). This is not uncommon in global expression datasets. Importantly, the direction of expression
(up- or down-regulated) were similar by either analysis. Therefore, discussion of these genes
will be based on the differential expression obtained in the RNAseq analysis.
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SperinA 6 was elevated in liver of SPI-fed rats (Table 2). This molecule belongs to the large
family of protease inhibitors called serpins. Serpin-like genes have been described in numerous
phyla, from viruses to animals (Law et al. 2006). Most serpins inhibit serine proteases, but there
are some rare serpins performing a non-inhibitory function. SerpinA 6 which encodes an

-

globulin also called corticosteroid-binding globulin (CBG) or transcortin, is primarily produced in
the liver and to a lesser extent in the placenta, kidney, endometrium, lung, pituitary, and
hypothalamus (Gagliardi et al 2010; Hammond et al. 1987; Law et al. 2006). SerpinA 6 is a
transporter of several anti-inflammatory steroids and progesterone in plasma (Henley and
Lightman 2011). Under normal conditions in humans, about 80% to 90% of cortisol is bound to
SerpinA 6 with high affinity (Gagliardi et al. 2010; Hammond et al. 1987; Richard et al. 2010). By
regulating the free cortisol concentration in blood, SerpinA 6 controls the bioavailability of
corticosteroids, thus acting as a buffer during a secretory surge that can increase the levels of
cortisol or as a reservoir of this corticosteroid during periods of decreased secretion (Gagliardi
et al. 2010; Henley and Lightman 2011).
SerpinA 6 levels in blood are associated with body mass index, insulin resistance, serum
levels of interleukin-6, and adiponectin as well as proliferation and differentiation of
preadipocytes (Braun et al. 2010). The role of SerpinA 6 as a simple transporter is starting to
change in the last few years. SerpinA 6 is the substrate of elastase that is released in high
concentration by activated neutrophils at sites of inflammation. Once elastase cleaves SerpinA
6, the binding affinity for cortisol is reduced 10-fold, releasing cortisol at the inflammation site as
a result. Thus, SerpinA 6 might have a key role in preventing tissue damage during inflammation
such as that occurring in NAFLD, since cortisol modulates inflammatory response (Braun et al.
2010; Gagliardi et al. 2010). The role of SerpinA 6 as an indirect anti-inflammatory molecule
could shed some light on our research, partially explaining why there are no signs of
inflammation on the SPI-fed rat liver.
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IL-33 belongs to the IL-1 superfamily of cytokines expressed in healthy vascular endothelial
cells, epithelial cells, fibroblasts and smooth muscle cells (Haraldsen et al. 2009; Miller 2011).
IL-33 is expressed primarily in cells from tissues involved in the production and maintenance of
a barrier. When the barriers are damaged, IL-33 behaves as an alarm, being released to initiate
the acute local inflammation and tissue-repair process. IL-33 has a function as a ligand for the
Th2-associated ST2 receptor activating NFkB and mitogen-activated kinases. IL-33 also
functions as a nuclear factor regulating gene transcription (Cayrol and Girard 2014; Haraldsen
et al. 2009; Martin and Martin 2016; Miller 2011). IL-33 was reported to be a regulator of hepatic
ischemia and reperfusion injury related with the activation of NFκB, p38 MAPK, cyclin D1, and
Bcl-2 that restricts liver injury and decreases inflammation promoters in mice (Sakai et al. 2012).
In a recent review, Sun et al. (Sun et al. 2017) reported that IL-33 may serve a protective
role in fatty liver disease. Pejnovic et al. (Pejnovic et al. 2016) developed an NAFLD mouse
model through feeding a high fat diet. Treating these NAFLD mice fed a high fat diet with IL-33
was able to ameliorate hepatic steatosis as well as insulin resistance and glucose intolerance
(Pejnovic et al. 2016). Furthermore, treating genetically obese mice with IL-33 reduced fat
accumulation (adiposity), possibly through induction of Th2-mediated cytokine production (Miller
et al. 2010). Thus, it is possible that the elevation of IL-33 in SPI-fed rats played a role in the
reduction of liver steatosis compared to CAS-fed rats in the present study.
There are some studies relating consumption or treatment with phytoestrogens with
immune response, mostly when members of IL1 superfamily are involved, and chronic diseases
and other conditions, such as asthma, inflammatory bowel diseases, and radiation-induced
bone marrow failure (Ha et al. 2013; Martin and Bolling 2015; Sandoval et al. 2010; Tanaka and
Takahashi 2013). Nevertheless, less is known regarding the effects of IL33 in the presence of
phytoestrogens or any isoflavones in NAFLD.
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PRSS8 was up-regulated in liver obtained from rats fed the CAS-based diet (Table 2, Figure
2). PRSS8, also known as prostasin and channel-activating protease 1 (CAP1), is a trypsin-like
serine peptidase. PRSS8 was first identified as a secreted prostate gland product (Tong et al.
2004; Yan et al. 2014). In humans, PRSS8 mRNA expression has been detected in prostate,
liver, salivary gland, kidney, lung, pancreas, colon, bronchus, and in some cells from the kidney
(Chen and Chai 2012; Yu et al. 2014). Uchimura et al. reported in 2014 that upregulation of
PRSS8 protected mice from chronic inflammation by reducing toll-like receptor 4 (TLR4)
attachment to the endoplasmic reticulum (Uchimura et al. 2014). Furthermore, down-regulation
of PRSS8 in mice fed a high fat diet contributed to hepatic insulin resistance and development
of diabetes. Thus, in the present study, down regulation of PRSS8 in the SPI-fed rats may not
be beneficial with respect to preventing liver steatosis. Possibly, the down regulation of PRSS8
expression in SPI-fed rats indicates there is no signal needed to suppress inflammation relative
to the extensive liver steatosis present in the CAS-fed rats. Mechanistic studies will need to be
conducted to verify this hypothesis.
AJUBA, also known as ajuba LIM protein, belongs to the LIM protein family, that is
characterized by tandem homologous C-terminal LIM domains and a unique N-terminal preLIM
region rich in glycine and proline residues (Fan et al. 2015). This arrangement contributes to the
linking and/or strengthening of epithelial cell-cell junctions in part by linking adhesive receptors
to the actin cytoskeleton. The LIM motif is a double zinc finger structure and functions as a
protein-protein interface (Fan et al. 2015).
In humans, AJUBA expression was elevated in patients exhibiting nonalcoholic
steatohepatitis (NASH) compared to patients with healthy liver, but there were no differences in
expression between patients with NAFLD compared to those with healthy liver (Arendt et al.
2015). Thus, the upregulation of AJUBA in CAS-fed compared to SPI-fed rats is indicative of
severe liver steatosis and concurs with the findings by Arendt et al. (Arendt et al. 2015).
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A third gene that was up-regulated in CAS-fed rats (down-regulated in SPI-fed rats) was
CSF2RB (Table 2, Figure 2). The CSF2RB protein is the common beta chain subunit of the high
affinity receptor for Interleukin 3 (IL-3), IL-5, and granulocyte-macrophage colony-stimulating
factor receptor (GM-CSF receptor), that are all cytokines and important regulators of
hematopoiesis and inflammation (Akdis et al. 2011; Woodcock et al. 1994). Tallino et al.
reported that a copper deficient diet up-regulated CSF2RB in a NAFLD mature rat model
(Tallino et al. 2015). Thus, the increase in CSF2RB in CAS-fed rats in the present study agrees
with Tallino et al., with CAS-fed rats exhibiting increased liver steatosis compared to SPI-fed
rats.
CYP2C12, which belongs to the cytochrome P450 superfamily (CYP) of microsomal
enzymes broadly present in both prokaryotes and eukaryotes and that is classified in families
and subfamilies based on amino acid sequence similarities (Honkakoski and Negishi 2000; Xu
et al. 2005), was upregulated in CAS-fed rats in RNAseq and RT-qPCR data (Table 2) and in
shotgun proteomics (see Figure 3). The proteins of this superfamily function as monooxygenases, playing a major protective role from toxic and oxidative damage in the liver,
intestine, kidney, and lung. CYPs act in a vast range of functions from the synthesis and
metabolism of fatty acids, steroid hormones, cholesterol, bile acids, and vitamins to drug
metabolism and detoxification from xenobiotics (Honkakoski and Negishi 2000; Xu et al. 2005).
Since CYP expression and activity can be affected by components present in the diet which in
turn can lead to changes in drug metabolism and in the development of several conditions such
as cancer, cardiovascular, and fatty liver disease, there is a great abundance of studies
involving the interaction between CYPs and specific dietary components (Hamilton-Reeves et
al. 2007; Kishida et al. 2004; Li et al. 2007; Liu et al. 2016; Ronis 2016).
Current studies indicate that consumption of SPI protects against cancer by downregulating the expression of CYP1 family members (Rowlands et al. 2001). There are also
several reports where the expression of CYP3 and CYP4 families was activated or up-regulated
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by a SPI-diet (Badger et al. 2008; Li et al. 2009; Mezei et al. 2003; Ronis et al. 2004). In a
recent study, it was demonstrated that although SPI maternal consumption mitigates serum lipid
levels on rat male offspring mainly through the up-regulation of important CYPs such as
CYP3A1, the liver protein CYP2C12 was down-regulated in the SPI-fed group compared to the
CAS-fed group (Won et al. 2017). This finding coincides with our results in this study.
The downregulation of TNFRSF12A in SPI-fed rats observed in the RNAseq data (Table 2)
clearly points to a protective role of soy against development of liver steatosis based on wellknown functions of this molecule. TNFRSF12A, also known as tumor necrosis factor-like weak
inducer of apoptosis receptor (TWEAKR) and fibroblast growth factor inducible 14 (Fn14), is a
transmembrane protein with a weak induction of apoptosis in some cell types. The human
TNFRSF12A gene is expressed at relatively low levels in normal liver tissue but at high levels in
liver cancer cell lines and in hepatocellular carcinoma specimens (Feng et al. 2000). Also, the
expression of this protein increases in human liver tissue exhibiting NAFLD (Jakubowski et al.
2005; Wiley et al. 2001). This behavior could explain in part the fact that TNFRSF12A was
down-regulated in our study in the SPI-fed rat livers that showed no sign of inflammation or
fibrosis. TNFRSF12A promotes angiogenesis and the proliferation of endothelial cells and
modulates cellular adhesion to matrix proteins and inhibits growth and migration in vitro (Feng et
al. 2000). Nuclear factor of activated T-cells 1 (NFAT1), a type of transcription factor, regulates
the expression of TNFRSF12A and its ligand, tumor necrosis factor-like weak inducer of
apoptosis (TWEAK), with Lipocalin 2 to increase breast cancer cell invasion (Gaudineau et al.
2012).
Lipocalin 2 (LCN2) was upregulated in CAS-fed rats in the RNAseq data (Table 2). This
molecule belongs to the heterogeneous lipocalin (LCN) family whose members display
differences at the sequence level but remain similar at the structural level (Flower 1996). The
LCN family is involved in the transport of small hydrophobic molecules and other various
functions (Borkham-Kamphorst et al. 2013). LCN2 is a secretory glycoprotein, with different
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functions ranging from transport of small molecules such as fatty acids, steroids, thyroid
hormone, and retinoids, to a key role in the innate immunity, iron trafficking, and induction of
apoptosis (Auguet et al. 2011; Flower 1996) . LCN2 is considered an adipocytokine (Alwahsh et
al. 2014; Auguet et al. 2013) and reported to be secreted as a cytokine from the liver and kidney
as well as from neutrophils, and macrophages (Esteve et al., 2009; Wang et al. 2007). Cellbased immunohistochemistry studies affirm that the main source of LCN2 in liver are the injured
hepatocytes themselves (Borkham-Kamphorst et al. 2013). The presence of LCN2 protein in
blood and urine is an early biomarker of acute kidney injury and other pathologic conditions
(Asimakopoulou et al. 2014; Borkham-Kamphorst et al. 2013; Makris et al. 2012).
It was reported that LCN2 is likely to be one of the adipokines implicated in the
pathogenesis of NAFLD since it is secreted from both adipose tissue and the liver (Auguet et al.
2013). In a diet-inducible fatty liver rat model, the researchers found a strong correlation
between a high calorie diet and an increase or up-regulation of hepatic LCN2, elevated
indicators of apoptosis, mitochondrial dysfunction, and lipid peroxidation in the hepatic cells
(Alwahsh et al. 2014). This study was similar to ours, where LCN2 was down-regulated in the
SPI-fed rats with no sign of steatosis nor inflammation.
In summary, we have validated gene expression in an RNAseq study with PCR analysis
that investigated global gene expression in liver obtained from obese rats fed diets containing
CAS or SPI. The SPI-fed rats became obese but exhibit less NAFLD. Within the group of genes
that were targeted for validation, it is clear there are novel findings that are being reported, such
as with the up-regulation of NPTX2 in SPI-fed rats. There are also genes whose transcribed
proteins would be protective of liver cells based on either up- or down-regulation. Our future
plan will be to take full advantage of the Ingenuity Pathway Analysis program to reveal
fundamental mechanisms, i.e., pathways, upstream regulators that were differentially expressed
in the two groups of rats to reveal what aspects were being altered by SPI. We also have
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conducted shotgun proteomics analyses that will enable a proteogenomic picture to be
developed in the prevention of NAFLD afforded by the SPI-based diet.
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Tables and Figures
Table 1. Comparison of mean mRNA expression (fold difference) in liver of obese rats fed soy
protein isolate (SPI) or casein (CAS) diets for 8 weeks obtained by RNAseq and RT-PCR.
These mean values were used in correlation analysis (see Fig. 1).
RNAseq
PCR
Gene Symbol Gene Name
(Fold Diff)
(Fold Diff)
NPTX2
Neuronal pentraxin 2
1.88*
5.89*
GPT
Glutamic-pyruvic transaminase
2.02*
1.96*
INMT
Indolethylamine N- methyltransferase
1.83
6.69
HAL
Histidine ammonia-lyase
1.85*
4.33*
Serpina6
Serpin family A member 6
1.51*
0.38
IL33
Interleukin 33
1.52*
0.66
PRSS8
Protease, Serine 8
-5.71*
-18.52*
AJUBA
Ajuba LIM protein
-2.65*
-2.71*
CSF2RB
Colony stimulating factor 2 receptor b
-2.45*
-2.71
CYP2C12
Cytochrome P450, family 2 receptor b
-2.45*
-2.71*
LCN2
Lipocalin 2
-2.45*
-4.76
TNFRF12
TNF receptor superfamily member 12A
-2.30*
-1.96
1
Values represent mean of n=8.
Positive and negative values indicate up- and down-regulation of gene expression, respectively,
in livers of obese rats fed soy protein isolate-based vs casein-based diets. *Indicates significant
difference (P < 0.05) between dietary groups.
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Table 2. Oligonucleotide PCR primers based on the Rattus norvegicus genome.

Gene
NPTX2

Accession No.1
NM_001034199.1

GPT

NM_031039.1

INMT

NM_001109022.1

HAL

NM_017159.1

PRSS8

NM_138836.1

Ajuba

NM_053503.1

CSF2RB

NM_133555.1

Cyp2c12

NM_031572.1

Serpina 6

NM_001009663.1

IL33

NM_001014166.1

TNFRSF12A

NM_181086.3

LCN2

NM_130741.1

18S

NR_046237.1

Product
Size
(bp)
59

Primer sequence
TCCGGGCACAAGAGATCATC
GATGTTTCCAGGCATGTTCGT
GCCCGGGAGTGGCTTT
GCAGAATGGTCATCCGGAAA

Orientation
Forward
Reverse
Forward
Reverse

CCCAAAGACTACCTGACCACC
TCCCCCTACACCTCCTGTAGA
TCATCGAGCACGTGGAACAA
ATCCAGGGCCTTACTACGGA
CCTACAATGGCGTCCACGTT
TGACACCACCCATTGATTTGA

Forward
Reverse
Forward
Reverse
Forward
Reverse

120

AGGCCATGGGGAAGTCCTAT
CGGGGCGTAATTTTTGTGGT
CCCAAAGCTGGGGAGAAGAAA
AACAGAGACGGTGTACTGGC
TTCTCAGCAGGAAAACGGAAATG
TCGATGTCCTTTGGATCAGACAG

Forward
Reverse
Forward
Reverse
Forward
Reverse

137

TCCTCAGAGGCATATGGGAACT
AGGGGAAGACTGAGTCACGA
CAGAATCTTGTGCCCTGAGC
CGGAGTAGCACCTTATCTTTTTCT
ACTTCAGGATGCTATGGCCC
CAGTCTCCTCTATGGGGGTAGTAA

Forward
Reverse
Forward
Reverse
Forward
Reverse

144

CAAGTGGCCGACACTGACTA
CCCCTTGGTTCTTCCGTACA
AGTCCCTGCCCTTTGTACACA
GCCTCACTAAACCATCCAATCG

Forward
Reverse
Forward
Reverse

105

69

59

139
59

126
122

124
132

60

Figure 1. Liver histology. Obese Casein-fed rats (Cas) versus Obese Soy-fed rats
(Soy) for 8 weeks Liver steatosis.

Figure 2. Regression analysis of mean values obtained by PCR and by RNAseq
analysis.
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Figure 3. Targeted mRNA expression (RT-PCR) of genes listed in Table 1 determined in the
liver of Zucker rats fed diets containing casein (CAS) or soy protein isolate (SPI) for 8
weeks. Bars represent mean ± SE (n=8); * P < 0.05, ** P < 0.01, *** P < 0.001

71

Figure. 4 Energy Production, Lipid Metabolism, and Small Molecule Biochemistry Network
built with IPA program from shotgun proteomics data (Kozaczek et al. (Kozaczek et al. 2018),
unpublished) that was determined on liver samples from the same SPI- and CAS-fed animals
as described in the present study. Proteins in red were up-regulated in the SPI-fed rats and
proteins in green were up-regulated in the CAS-fed rats. The blue circles highlight two
molecules, GPT and CYP2C12, that exhibited differential protein expression (1.3-fold
difference, P < 0.05) concurs with RNAseq and RT-qPCR data. Molecules in gray were
detected but were below the cut off values of fold difference and P < 0.05. Molecules in white
are part of the network but were not detected in the proteomics data. The network shows their
interactions with other proteins from the dataset.
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CHAPTER 4
Long-Term Soy Protein Isolate Intake Reduces Liver Steatosis by Changing Global Gene
Expression in Obese Zucker Rats
Targeted Journal will be: Frontiers of Nutrition
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4.1 Abstract
To understand how soy protein isolate (SPI) reduced liver steatosis in male obese Zucker rats,
we conducted global gene expression (RNAseq) analysis on liver samples of male rats fed
either the SPI or a control casein (CAS)-based diet (n=8 per group) for 16 wks. Liver
transcriptomic was analyzed using an Ilumina HiSeq system with 100 base paired end reads for
sequencing. Bioinformatics was conducted using Ingenuity Pathway Analysis (IPA) software
(Qiagen, CA) with P < 0.05 and 1.3 fold differential expression cutoff values. Regression
analysis between RNAseq data and targeted mRNA expression analysis of 12 top differentially
expressed genes (from the IPA program) using quantitative PCR (qPCR) revealed a significant
regression analysis (r2=0.55, P< 0.001). In addition, all qPCR values had qualitatively similar
direction of up- or down-regulation compared to the RNAseq transcriptomic data. An
assessment of diseases and functions based on differentially expressed target molecules in the
dataset revealed that lipid metabolism was predicted to be enhanced whereas inflammatory
response was predicted to be inhibited in SPI-fed compared to CAS-fed rats at 16 weeks.
Using the upstream regulator analysis and regulator effects functions of the IPA program
enables the prediction of a number of upstream regulators (e.g. transcription regulators) that
could be playing important roles in attenuating or promoting liver steatosis due to SPI or CAS
diets. Examples of upstream regulators that were predicted to be activated (based on
expression of down-stream target molecules) that were linked to increased conversion of lipid
and transport of lipid in SPI-fed rats included hepatocyte nuclear factor 4 alpha and aryl
hydrocarbon receptor. Examples of upstream regulators that were predicated to be activated in
CAS-fed rats that were linked to predicted activation of phagocytosis and neutrophil chemotaxis
included colony stimulating factor 2 and tumor necrosis factor. The results provide clear
indication that long-term SPI-fed rats exhibited diminished inflammatory response and increased
lipid transport in liver compared to CAS-fed rats that likely would contribute to reduced liver
steatosis in this obese Zucker rat model.
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4.2 Introduction
Excess accumulation of fat in the liver, liver steatosis, a condition strongly linked to
obesity, can be divided in two major categories: Alcoholic Fatty Liver Disease and Non-Alcoholic
Fatty Liver Disease (NAFLD). Alcoholic liver disease occurs due to alcohol abuse over extended
period of time (Szabo, 2015), whereas NAFLD can be described as an accumulation of lipid in
the liver cells that is not provoked by alcohol intake (Castaño-Rodríguez et al., 2017). In the last
decade, NAFLD has gained more attention due to its high connection with other disorders, such
us an increase in the lipids in the circulation, excess body weight, insulin resistance, and
inflammation, diabetes type II, and vascular disorders (Castaño-Rodríguez et al., 2017;
Romero-Gómez et al., 2017) that when present at the same time contribute to a larger disorder
called Metabolic Syndrome. Metabolic syndrome has its origin in obesity with hereditary
components and sedentary behavior (Hales et al., 2017).
The mild steatosis in NAFLD if left untreated can lead to non-alcoholic steatohepatitis
(NASH), and finally to irreversible damage to the liver due to cirrhosis. The development of
NAFLD takes place in two stages; Stage 1) Insulin resistance develops that is accompanied by
lipid accumulation in the liver in the form of triglyceride, and Stage 2) Mitochondrial dysfunction
with mitochondrial reactive oxygen species production promotes oxidative stress leading to
inflammation and hepatic fibrosis (Feng et al., 2017; Musso et al., 2012). Recently, a revision of
the progression of pathogenesis has been proposed in which NAFLD can be tentatively
diagnosed in patients with elevated liver enzymes and by imaging in the absence of other
causes of liver disease. However, a definitive diagnosis can only be made by liver biopsy
(Serviddio et al., 2008; Weiß et al., 2014). Estimations of the prevalence suggest that NAFLD
could be the most common form of chronic liver disease in adults in the US, Asia, Australia, and
Europe that may affect 10% to 35% of the worldwide population (Bellentani and Marino, 2009).
There is also increasing concern of NAFLD as a significant form of liver disease in pediatric
populations (Cornier et al., 2008; Kleiner et al., 2005).
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Although short-term feeding a diet containing soy protein isolate (SPI) specifically
targeted and halted the development of liver steatosis in male and Female obese Zucker rats
compared to those fed a casein (CAS)-based diet (Hakkak et al., 2015), the exact mechanisms
responsible for SPI-mediated amelioration of liver steatosis is not understood. To better
understand fundamental mechanisms by which SPI attenuated NAFLD, we have conducted
global gene expression (RNA seq) analysis on liver tissue obtained from obese rats fed the SPIand CAS-based diets for 8 weeks (Kozaczek et al., 2019). The results of this study indicated
gene expression favoring or promoting anti-inflammatory activities in SPI-fed rats and
inflammatory activities in CAS-fed rats and consistent with the observation of reduced liver
steatosis in SPI-fed rats (Hakkak et al., 2015). In the present study, we report on global
expression analysis of liver obtained after long term (16 weeks of feeding CAS- and SPI-based
diets) to obese rats to intensify efforts to reveal fundamental mechanisms associated with
development of liver steatosis and amelioration of liver steatosis afforded to obese rats
consuming the SPI-based diet.
4.3 Materials and Methods
4.3.1. Experimental Design
All animal protocols were approved by the Institutional Animal Care and Use Committee
at the University of Arkansas for Medical Sciences (Protocol code number 3242; approved on
12/6/2011). Liver tissue was obtained from male obese Zucker rats from a previous study
(Hakkak et al. 2015). Briefly, rats (6 weeks old) were purchased from Harlan Laboratories
(Indianapolis, IN). After one week of acclimation, rats were randomly assigned to either a casein
(CAS) diet or soy protein isolate (SPI) diet. They were housed in individual cages and provided
the diets ad libitum for 16 weeks and all rats were humanely killed, and liver samples obtained,
and flash frozen in liquid nitrogen and stored at −80°C.
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4.3.2. Transcriptomic Analysis
A phenol-chloroform solution was used to extract RNA from liver samples. A 1% agarose
gel was used to evaluate the quality of RNA and concentrations were assessed with Take 3
micro volume plate with a Synergy HT multi-mode microplate reader (BioTek, Winooski, VT).
RNA sequencing (RNAseq) of RNA samples was conducted using an Illumina HiSeq 100 base
pair paired end read at the Research Support Facility (Michigan State University, East Lansing,
MI). The CLC Genomics Workbench 8 software that incorporates the pipeline recommended by
Mortazavi et al. (2008) was used to map the reads to Rattus rattus genome assembly (version
4). The RPM data was transformed using log2 to stabilize the variance and then performed a
further quantile normalization. Over 1200 transcripts were differentially expressed (> 1.3 fold
difference and P < 0.05). Ingenuity Pathway Analysis (IPA) commercial software (Qiagen, CA)
was used to help in the interpretation of the dataset.
4.3.3. Real time quantitative PCR (RT-qPCR)
Targeted gene expression was conducted using RT-qPCR) to validate transcriptomic
results. Briefly, RNA was extracted from liver samples using Trizol reagent (#15596018, Life
Technologies) following the manufacture’s recommendations, treated with DNAase, and reverse
transcribed (catalog #95048-100, Quanta Biosciences). Next, the cDNA (RT products) were
amplified by RT-qPCR (Applied Biosystems 7500 Real-Time PCR system) with Power SYBR
green Master Mix (catalog #4312074, Life Technologies). Primers used in this study, including
the 18S ribosomal housekeeping gene, are shown in Table 1. The cycling conditions for the RTqPCR were as follows: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of a two-step
amplification program with 95°C for 15 s and 58°C for 1 min. To exclude contamination with
unspecific PCR products we used melting curve analysis applying the dissociation protocol from
the Sequence Detection system. The 2–ΔΔCt method was chosen to establish the relative
expressions of target genes in this study (Schmittgen and Livak, 2008). Relative mRNA
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expression was obtained by normalizing CAS expression values to 1.0 for comparison with the
SPI group.
4.3.4. Statistical evaluation
The analysis of qPCR data and regression analysis between qPCR and transcriptomic
(RNAseq) was assessed with the software Graph Pad Prism version 6.00 for Windows, La Jolla
California USA, and Student’s t-test. Differences were considered significant at P<0.05.
Upstream regulator analysis by IPA is based a combination of a) the number and degree
of differential expression of downstream target molecules in the existing dataset, and b) on prior
knowledge of expected effects between transcriptional regulators and their target genes from
published literature citations that have been curated and stored in the IPA program. Upstream
regulator analysis determines how many known targets or regulators are within the user’s
dataset and compares each differentially expressed molecule to the reported relationship in the
literature. If the observed direction of change is mostly consistent with either activation or
inhibition of the transcriptional regulator, then a prediction is made, and an activation z score
generated that is also based on literature-derived regulation direction (i.e. “activating” or
“inhibiting”). Activation z scores > 2.0 indicate that a molecule is activated whereas activation z
scores of < -2.0 indicate that a target molecule is inhibited. The p-value of overlap measures
whether there is a statistically significant overlap between the dataset molecules and those
regulated by an upstream regulator is calculated using Fisher’s Exact Test, and significance is
attributed to p-values < 0.05.
4.4 Results
4.4.1. Top differentially expressed genes: RT-qPCR and RNAseq data
RT-qPCR was conducted on 13 of the most differentially expressed genes provided by
Ingenuity Pathway Analysis (IPA) in the RNAseq dataset included NPTX2, IL33, PRSS32,
Resp18, RGN, SULT2A1, AMDHD1 that were up-regulated, and Gnai, PRSS8. Cidea,
MAGEE1, Sdr16c6 and HIVEP2 that were down-regulated in the SPI-fed compared to CAS-fed
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rats. Fold differences in mRNA expression by RNAseq and RT-PCR for top up- and downregulated genes in liver of the SPI-fed rats compared to CAS-fed rats are shown in Table 2.
Regression analysis of mean values shown in Figure 1 indicate that there was a significant
correlation (r2 = 0.55, P < 0.001) between targeted PCR and RNAseq data expression in the
most differentially expressed genes in the transcriptomic dataset.
4.4.2 Upstream Regulators
Predictions of activation or inhibition of upstream regulators provide insight into potential
mechanisms in this study by which SPI feeding ameliorates liver steatosis in NAFLD. A partial
list of upstream regulators predicted to be activated or inhibited from the RNAseq data obtained
in SPI-fed rats vs CAS-fed obese rats after 16 weeks of feeding is presented in Table 3. Top
upstream regulators predicted to inhibited in SPI-fed rats include tumor necrosis factor (TNF),
Interferon Gamma (IFNG), colony stimulating factor 2 (CSF2), resistin-like beta (RETNLB) and
TNF receptor 1 beta (TNFRSF1B) (Table 3A). Top upstream regulator genes predicted to be
activated in SPI-fed rats include Acyl-CoA (ACOX1), hepatocyte nuclear factor 4 alpha
(HNF4A), insulin induced gene 1 (INSIG1), HNF1 homeobox A (HNF1A), immunoglobulin G
(IgG), and Aryl hydrocarbon receptor (AHR). A complete list of upstream regulators predicted to
be inhibited or activated in the SPI-fed rats is provided in Supplementary Table 1A and 1B,
respectively. There were 32 genes predicted to be inhibited in SPI-fed rats (Supplementary
Table 1A) and 15 genes that were predicted to be activated in the SPI-fed rats (Supplementary
Table 1B). Each of these predictions for upstream regulators point toward fundamental
mechanisms that are involved in attenuation of liver steatosis provided by feeding the SPI to the
obese rats.
A heat map of the RNAseq data generated by IPA software is presented in Figure 2.
Blue represents diseases and functions that were predicted to be inhibited whereas orange
represents those predicted to be activated in the SPI-fed vs. CAS-fed rats. The darker the color
the stronger to prediction based on activation Z-scores calculated by the Ingenuity Pathway
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Analysis program. A breakdown of specific functions predicted to be activated or inhibited in the
dataset (with activation Z-scores of < -2.0 or > 2.0, respectively) within two broad diseases and
functions classification (lipid metabolism and inflammatory response) is presented in Figure 3.
Each of the specific processes listed with lipid metabolism would be predicted to be enhanced in
the SPI-fed rats whereas each of the processes listed under inflammatory response would be
predicted to be inhibited in the SPI-fed rats. The list of functions under lipid metabolism is
consistent with the observation of reduced liver steatosis in the SPI- compared to CAS-fed rats.
Furthermore, the list provided under inflammatory response clearly indicates that inflammation
would be inhibited in the SPI-fed rats.
The activation Z-scores of processes presented in Figure 3 were calculated by the IPA
program based on differential expression of genes in the dataset and on the relationships of
gene expression with the function reported in the scientific literature. An example of one of the
networks generated by the IPA program analysis of the dataset for efflux of cholesterol is
presented in Figure 4A. The IPA program can also provide predictions of activation or inhibition
of upstream transcription factors in regulator networks that connect transcription factors to
specific diseases or function through differentially expressed molecules in the functional
network. In the example shown in Figure 4B, the transcription factor RETNLB (restin-like protein
beta) was predicted to be inhibited in SPI- compared to CAS-fed rats. Additional examples of
regulator networks are presented in Figures 5 and 6. In Figure 5, hepatocyte nuclear factor one
(HNF1) homeobox A (HNF1A) and HNF4A are transcription factors predicted to be activated in
the SPI-fed rats that would contribute to lipid transport from the liver. Two regulator networks
indicating that phagocytosis and chemotaxis of neutrophils are predicted to be inhibited in SPIfed rats through down-regulation (inhibition) of colony stimulating factor 2 (CSF2) and tumor
necrosis factor (TNF) are shown in Figure 6.
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4.5 Discussion
NAFLD is characterized by an unhealthy accumulation of lipids within hepatocytes
accompanied by inflammation of the liver tissue. In this study, we demonstrated that a long-term
feeding of SPI enhances lipid metabolism and decreases several components of inflammation
response (Fig. 3). Several functions that were predicted to activated (e.g. lipid transport, efflux,
and conversion of lipid) in SPI-fed rats are processes that could reduce lipid accumulation in
hepatocytes. Similarly, processes and functions involved in inflammatory response such as
phagocytosis, chemotaxis of neutrophils, and immune response of cells, were inhibited in SPIfed rats thus ameliorating NAFLD symptoms. A wide range of molecules were predicted to be
activated or inhibited in liver of obese rats fed an SPI- compared to CAS-based diet. As
discussed below, these predictions point towards mechanisms by which SPI ameliorates liver
steatosis and can serve as hypotheses to be tested in future studies.
Acyl-CoA Oxidase 1 (ACOX1) (Table 3), also called Peroxisomal acyl-coenzyme A
oxidase 1, is a transcription factor predicted to be activated (z score = 4.04) in liver of rats
provided a SPI diet. Unlike most medium and long chain fatty acids whose oxidation occurs in
the mitochondria, very long fatty acids are degraded in peroxisomes (Vluggens et al., 2010).
ACOX1 catalyzes the first step of the peroxisomal beta-oxidation of very long fatty acids in the
fatty acid degradation pathway (Zuo et al., 2007). A study with a point mutation of ACOX1
showed that beta-oxidation provides a clear link between fat metabolism and immune
responsiveness (Moreno-Fernandez et al., 2018). In this study, the authors found an increase in
the hepatic neutrophil infiltration when ACOX1 was not functioning properly. This finding is
consistent with the results in our study predicting decreased hepatic migration and chemotaxis
of neutrophils (Fig. 3 and 6B) when ACOX1 is activated in SPI treatment. In addition, a recent
study concluded that ACOX1 is the post transcriptional target of miR-222 (Wang et al., 2019), a
microRNA already being investigated in relationship with NASH, cancer and inflammatory
diseases (Song et al., 2017); however, not strongly related to NAFLD as with NASH and HCC
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(de Conti et al., 2017). The aforementioned research found that when miR-222 targets ACOX1 it
inhibits it, and accumulation of triglycerides is promoted (Wang et al., 2019). These results
concur with findings in the present study in which ACOX1 is predicted to be highly activated in
SPI treatment; thus, preventing accumulation of triglycerides and inflammation. Since many
microRNAs are involved in the pathology of insulin resistance, NAFLD, and fibrosis (Su et al.,
2018) it would be reasonable to link a decreased expression or inhibition of miR-222 by the
consumption of a diet high in soy proteins, although the mechanisms remain unknown. Further
research its needed.
Both Hepatocyte Nuclear Factor Alpha 4 (HNF4A) and 1 (HNF1A) (Table 3B) are
upstream regulators predicted by IPA program to be strongly activated in our study (z score =
3.44 and 2.55 respectively) in the liver of rats provided a SPI diet. HNF4A is a nuclear
transcription factor known to regulate several hepatic genes including the related transcription
factor HNF1A (Figure 5) and other genes related to lipid metabolism (Krapivner et al., 2010).
There is evidence supporting HNF4A as a universal transcription regulator of hepatic
cytochrome P450 (CYP) genes (Jover et al., 2001). HNF1A is mainly expressed in liver but also
in pancreas and the kidneys (Tan et al., 2019). HNF4A and HNF1A are major promoters of
hepatic differentiation and maturation (Deng et al., 2014; Patitucci et al., 2017). Involved in lipid
metabolism, HNF4A has been demonstrated to be a central gene in the network of NASH
connected to metabolic diseases (Baciu et al. 2017). Mutations in this gene have also been
linked with both diabetes type 2 and maturity onset diabetes of the young (MODY) (Yamagata,
2014). An amplification of this gene has been found to be associated with colorectal cancer
(Zhang et al., 2014). In the early 2000s, Lazarevich et al., not only found a strong correlation
between the downregulation or lack of function of HNF4A and the progression of HCC, but also
that restoration of HNF4A expression could reverse the HCC phenotype in a mouse model
(Lazarevich et al., 2004). In 2010, Ning et al., established that the forced expression of HNF4A
inhibits HCC and alleviates hepatic fibrosis probably through the repression of beta-catenin
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signaling pathway (Ning et al., 2010), and proposed the administration of HNF4A as a possible
future pathological treatment (Ning et al., 2010). The search for biomarkers for NAFLD derived
HCC has shown the same trend (Frades et al., 2015): an uncoupling of important transcription
factors including HNF4A. Our study predicts HNF4A to be highly expressed in SPI treatment,
along with the upregulation of several CYPs and apolipoproteins (Figure 5), which could be
exerting a protective influence against lipid accumulation in the liver tissue; thus, preventing
inflammation and the progression to NAFLD in the long-term.
Several components of inflammatory response were predicted to be inhibited in SPI-fed
rats compared with the control. For example, tumor necrosis factor (TNF) (Fig. 6 and Table 3),
is an upstream regulator predicted to be inhibited (z score = -3.37) in the livers of SPI-fed rats.
TNF is a pro-inflammatory cytokine secreted by a wide range of cell types able to be released
as a consequence of inflammatory stimuli (Walsh et al., 1991). This protein also promotes
apoptosis and necrosis, and is reactive towards endotoxins and bacterial lipopolysaccharide
(LPS) (Yang et al., 1997; Zhang et al., 2010), as it can be inferred from the direct effect TNF has
over lipopolysaccharide binding protein (LBP, Figure 6B). There are many ways TNF contributes
to NAFLD and NASH pathophysiology. TNF is a key promoter of other inflammatory cytokines
and molecules related with hepatic steatosis and fibrosis (Kakino et al., 2018). It has been
suggested that TNF increases hepatic fat deposition via activation or upregulation of sterol
regulatory element binding protein-1c (SREBP-1c) which in turn regulates fatty acid synthase
(FAS) (Endo et al., 2007). In addition, TNF has the ability to lower the activity of the insulin
receptor that contributes to the development of insulin resistance (Hotamisligil et al., 1996). In
addition, inhibition of TNF in NASH patients has been reported to be beneficial either
ameliorating or reversing the pathology (Satapathy et al., 2004). In a four year follow up study,
TNF serum levels were reported to be increased in NAFLD patients, and associated with the
stage of the disease in concordance with the literature (Seo et al., 2013). Our study not only
predicts a strong inhibition of TNF under a SPI diet (Figure 6B) but also the chemotaxis of
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neutrophils as a whole function is predicted to be inhibited. All the genes involved in this network
were found to be downregulated in this study (See Figure 6B for a full list of the genes).
Conversely, in the CAS-fed rat livers TNF might promote the chemotaxis of neutrophils by
directly participating in the upregulation of the same genes. Nevertheless, the underlying
mechanisms are not completely understood.
Colony stimulating factor 2 (CSF2) (Table 3A and Figure 6A), also known as
granulocyte-macrophage colony-stimulating factor (GM-CSF) was predicted to be inhibited in
SPI treatment at 16 weeks (activation z score = -2.29). Its receptor, CSF2 receptor beta
(CSF2RB) was found to be down-regulated at 8 weeks of SPI treatment (Kozaczek et al., 2019).
CSF2 is a cytokine involved in inflammatory response that modulates the production and
differentiation of macrophages and granulocytes (Arcuri et al., 2009; Francisco-Cruz et al.,
2014). Morrison et al. (2018) found a correlation of the up-regulation of CSF2 in humans and
Ldlr-/-.Leiden mice with NASH (Morrison et al., 2018). Thus, our study concurs with Morrison et
al. (2018) since CSF2 was predicted to be inhibited in the liver of rats fed the SPI diet (Figure
6A) in a pathological state previous to NASH. Conversely, our study predicts CSF2 to be highly
activated in the CAS-fed rats, which presented inflammation in liver tissue, and directly
promoting phagocytosis through the activation of important target molecules (see Figure 6A).
4.6 Conclusions
The results of the analysis conducted in this study provide a clear indication that longterm SPI feeding attenuates liver steatosis by enhancing fat metabolism and lipid transport from
the liver while simultaneously lowering activity of upstream regulator genes that would inhibit
inflammation. Each of the predictions of activation or inhibition of genes that were calculated
from expression of downstream molecules and literature citations of similar or dissimilar
relationships should be considered as hypotheses to be tested in future studies.
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4.8 Tables and Figures
Table 1. Oligonucleotide PCR primers based on the Rattus norvegicus genome.
Gene

Accession No.1

Primer sequence

Orientation

NPTX2

NM_001034199.1

Resp18

NM_019278.1

RGN

NM_031546.1

SULT2A1

NM_131903.1

PRSS32

NM_001106983.1

AMDHD1

NM_001191781.1

IL33

NM_001014166.1

Cidea

NM_001170467.1

PRSS8

NM_138836.1

Gnai1

NM_013145.1

HIVEP2

NM_024137.1

Magee1

NM_001079891.1

Sdr16c6

NM_001109356.1

18S

NR_046237.1

TCCGGGCACAAGAGATCATC
GATGTTTCCAGGCATGTTCGT
GCAGCGACATAAATGCCCAC
CAGAACATGCCTTGGGGTACA
AGCGAGTTGGTGTAGATGCC
GAACTTGGTTCCAATGGTGGC
GAGCTGGATTTGGTCCTCAAGT
CAGTCCCCAATAGTGCCTTTCC
CACAAATCAACCGCTCCCAC
TTCGAGAATGACCTGCTCCG
GTGGGCACTGATGGGCTTAT
CACCAAACCTGGCAAGATGC
CAGAATCTTGTGCCCTGAGC
CGGAGTAGCACCTTATCTTTTTCT
AGGCCTTGTTAAGGAGTCTGC
CATAAGCGCCCGCATAAACC
CCTACAATGGCGTCCACGTT
TGACACCACCCATTGATTTGA
TGCAAGCCTGCTTCAACAGA
AAGTCATTCAGGTAGTACGCCG
TACACTCTGGCTGCTATGCAC
GGGTGCATCAGGTTTCATCTGT
CCCACCTGGAGTGCATCTTT
GCCCATCTTTGGCCCATTTG
GCCATCTCTCACTTCTGGATTTG
CCAACGACTCCTGCTATGCT
AGTCCCTGCCCTTTGTACACA
GCCTCACTAAACCATCCAATCG

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
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Product
Size (bp)
59
136
83
134
127
123
124
84
59
70
93
134
101
60

Table 2. Comparison of mean mRNA expression (fold difference) in liver of obese rats fed soy
protein isolate (SPI) or casein (CAS) diets for 16 weeks obtained by RNAseq and RT-PCR.
These mean values were used in correlation analysis (see Fig. 1).
Gene Symbol

RNAseq

PCR

(Fold Diff)

(Fold Diff)

Gene Name

NPTX2

Neuronal pentraxin 2

3.80

7.01

PRSS32

Protease, Serine 32

2.28

1.50

Resp18

Regulated Endocrine Specific Protein 18

2.22

1.00

RGN

Regucalcin

2.22

1.29

SULT2A1

Sulfotransferase Family 2A Member 1

2.07

7.98

AMDHD1

Amidohydrolase Domain Containing 1

2.04

4.94

Gnai

G Protein Subunit Alpha I1

-3.24

-2.79

PRSS8

Protease, Serine 8

-3.09

-10.81

Cidea

Cell Death Inducing DFFA Like Effector A

-2.65

-7.68

MAGEE1

MAGE Family Member E1

-2.60

-1.03

-2.55

-3.10

-2.46

-2.65

Short Chain Dehydrogenase/Reductase Family
Sdr16c6
16C Member 6
Human Immunodeficiency Virus Type I Enhancer
HIVEP2
Binding Protein 2
1 Values

represent mean of n=8. Positive and negative values indicate up- and down-regulation
of gene expression, respectively, in livers of obese rats fed soy protein isolate-based vs caseinbased diets. *Indicates significant difference (P < 0.05) between dietary groups
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Table 3. A partial list of upstream regulators that were predicted to be inhibited (A) or
activated (B) in liver of rats provided a diet with soy protein isolate (SPI) compared to those
consuming a Casein-based diet for 16 weeks.
A
Upstream
Regulator
TNF
IFNG
CSF2
RETNLB
TNFRSF1B

Name
Tumor necrosis factor
Interferon Gamma
Colony Stimulating Factor 2
Restin like beta
Tumor necrosis factor receptor 1 beta

B
Upstream
Regulator
ACOX1
HNF4A
INSIG1
HNF1A
IgG

Name
Acyl-CoA oxidase 1
Hepatocyte nuclear factor 4 alpha
Insulin induced gene 1
Hepatocyte nuclear factor 1 homeobox A
Immunoglobulin G

AHR

Aryl hydrocarbon receptor
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Molecule Type
Cytokine
Cytokine
Cytokine
Other
transmembrane receptor

Molecule Type
Enzyme
transcription regulator
Other
transcription regulator
Complex
ligand-dependent nuclear
receptor

Activation
z-score
-3.37
-3.30
-2.29
-2.14
-2.00

Activation zscore
4.04
3.44
2.71
2.55
2.17
2.15

Figure 1. Regression analysis of RNAseq and PCR for targeted gene expression shown in Table 2.
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Figure 2. Heat map of diseases and functions arranged by Z-score with the IPA program. Functions in blue indicate inhibition while
those in orange indicate activation in SPI vs CAS-fed rats. Darker colors indicate greater activation or inhibition of function.
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Figure 3. Specific functions predicted to be activated associated with lipid metabolism (orange) or predicted to be inhibited (blue)
associated with inflammation in the liver of obese Zucker rats provided diets containing SPI-based diet compared to those provided a
CAS-based diet for 16 weeks.
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Figure 4. Gene expression networks leading to prediction of enhanced efflux of cholesterol in the RNAseq data in liver of 16 wk old
obese rats fed CAS- and SPI-based diets. (A) Network of gene expression in the dataset used to calculate the activation Z score of
efflux of cholesterol. Genes in pink or red were upregulated in the SPI-fed rats whereas those in green were down-regulated in SPIvs CAS-fed rats. Genes and their individual fold difference expression values are; APOA4 (apolipoprotein A4, 1.37), APOC2
(apolipoprotein C2, 1.36), APOM (apolipoprotein M, 1.38), cytochrome P450 family 7 subfamily A, member 1,1.98), FABP1 (fatty acid
binding protein 1, 1.41, FABP4 (fatty acid binding protein 4, -1.91), IL33, (Interleukin 33, 2.32), MSN (moesin,-1.32), PON1
(paraoxanase 1, 1.35), Scd2 (stearoyl-Coenzyme A desaturase 2, -2.42), VNN1, (vanin 1, -1.46). (B) This is a regulatory network that
predicts that RETNLB (restin like protein beta) transcription factor would be predicted to be inhibited in the SPI-fed rats.

Figure 5. Regulator network for transport of lipid with two upstream regulators. The hepatocyte
nuclear factors one (HNF1) homeobox A (HNF1A) and HNF1 factor 4 alpha (HNF4A) are
predicted to be activated and enhance lipid transport in SPI-fed rats through the network of
genes shown in the figure that include: APOH (apolipoprotein H, 1.32), Slco1a1 (solute carrier
organic ion transporter family member 1A1, 1.62), APOM (apolipoprotein M, 1.38), CYP7A1
(cytochrome P450 family 7 subfamily A member 1), FABP1 (fatty acid binding protein 1, 1.42),
AKR1C4 (also-keto reductase family member c14, 1.45), APOA4 (apolipoprotein A4, 1.37), and
APOC2 (apolipoprotein C2, 1.36).
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Figure 6. Regulator networks associated with specific components of inflammatory response of
phagocytosis (A) and chemotaxis of neutrophils (B) that were predicted to be inhibited in SPIfed compared to CAS-fed rats. In (A) the transcription factor colony stimulating factor 2 (CSF2)
was predicted to be in inhibited in SPI-fed rats based on downregulation of CSF2RB, ICAM1,
TGFB1 and CYBB. In (B), TNF (tumor necrosis factor) was predicted to be inhibited in SPI-fed
rats based on the expression of genes shown in the network. Genes and fold differential
expression in the regulatory networks are: CSFR2B (colony stimulating factor 2 receptor 2 beta
common subunit, -1,47), ICAM1 (intracellular adhesion molecule 1, -1.36), TGFB1 (transforming
growth factor beta 1, -1.33), CYBB (cytochrome b-245 beta chain, -1.57), SERPINB1 (serpin
family B member 1, -1.50), CD47 (CD47 molecule, -1.30), LGALS3 (glactin 3, -1.62), LCN2
(lipocalin 2, -2.10), PIK3CD (phosphoinositol-4,5 bisphoaste 3 kinase catalytic subunit D, -1.41),
PDE4B (phosphodiesterase 4B, -1.93), and LBP (lipopolysaccharide binding protein, -1.99).
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Supplementary Table 1. Upstream regulators predicted to be inhibited (A) or activated (B) in
the liver after 16 weeks in SPI-fed compared to CAS-fed Obese male Zucker rats.
A
Upstream
Regulator
TNF
IFNG
ERK
PRL

PPP1R13L
RUNX2

Name
Tumor necrosis factor
Interferon Gamma
MAPK group
Prolactin (member growth hormone)
Member epidermal growth factor
receptor
Protein Kinase C
MAPK interacting kinase 1
MYD88 inate immune signal transducer
adaptor
Vascular endothelial growth factor A
Tumor protein p53
Nuclear Factor kappa B
Synoviolin 1
RAC family small GTPase
Interleukin 1 beta
Colony Stimulating Factor 2
Jnk dimer
Interleukin 1 A
Transglutaminase 2
CD44 molecule
Lymphotoxin beta receptor
Plasminogen
GLI family zinc finger 1
Mitogen activated protein kinase kinase
kinase 1
Fibroblast growth factor 19
Enhancer of zeste 2 polycomb repressive
complex 2
Restin like beta
Interleukin 5
Protein kinase alpha
Tumor necrosis factor receptor 1 beta
Protein phosphatase 1 regulatory subunit
13 like
RUNX family transcription factor 2

CNR1

Cannaboid Receptor 1

ERBB2
Pkc(s)
MKNK1
MYD88
VEGFA
TP53
NFkB
SYVN1
RAC1
IL1B
CSF2
Jnk
IL1A
TGM2
CD44
LTBR
PLG
GLI1
MAP3K1
FGF19
EZH2
RETNLB
IL5
Pka
TNFRSF1B
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Molecule Type
Cytokine
Cytokine
Group
Cytokine

Activation
z-score
-3.37
-3.30
-3.11
-2.77

Kinase
Group
Kinase

-2.76
-2.68
-2.65

Other
growth factor
transcription regulator
Complex
Transporter
enzyme
cytokine
cytokine
group
cytokine
enzyme
other
transmembrane receptor
peptidase
transcription regulator

-2.57
-2.48
-2.42
-2.37
-2.33
-2.32
-2.32
-2.29
-2.28
-2.25
-2.24
-2.24
-2.24
-2.22
-2.22

kinase
growth factor

-2.20
-2.19

transcription regulator
other
cytokine
complex
transmembrane receptor

-2.18
-2.14
-2.02
-2.00
-2.00

transcription regulator
transcription regulator
G-protein coupled
receptor

-2.00
-2.00
-2.00

Supplementary Table 2. Upstream regulators predicted to be inhibited (A) or activated (B) in
the liver after 16 weeks in SPI-fed compared to CAS-fed Obese male Zucker rats. (Cont.)
B
Upstream
Regulator
ACOX1
HNF4A

ABCB4
 catenin
IgG

Name
Acyl-CoA oxidase 1
Hepatocyte nuclear factor 4 alpha
Polycystin 1, transient receptor potential
channel interacting
Insulin induced gene 1
Snail family transcriptional repressor 1
Hepatocyte nuclear factor 1 homeobox A
ATP binding cassette subfamily B
member 6
ATP binding cassette subfamily B
member 4
CTNN alpha
Immunoglobulin G

AHR
TRIM24
ZNF106
GPS2
SAFB

Aryl hydrocarbon receptor
Tripartite motif containing 24
Zinc finger protein 106
G protein pathway suppressor 2
Scaffold attachment factor beta

PKD1
INSIG1
SNAI1
HNF1A
ABCB6
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Molecule Type
enzyme
transcription regulator

Activation zscore
4.04
3.44

ion channel
other
transcription regulator
transcription regulator

2.89
2.71
2.56
2.55

transporter

2.39

transporter
group
complex
ligand-dependent nuclear
receptor
transcription regulator
other
transcription regulator
other

2.22
2.18
2.17
2.15
2.12
2.00
2.00
2.00

Chapter 5
A Comparison of Short and Long-Term Soy Protein Isolate Intake and its ability to reduce Liver
Steatosis in obese Zucker Rats through modifications of genes involved in inflammation and
lipid transport

5.1 Abstract: Transcriptomics (RNAseq) was conducted on liver samples from male obese
Zucker rats fed diets containing either soy protein isolate (SPI) or casein (CAS) for 8 and 16
weeks. Interpretation of the transcriptomic data was carried out using Ingenuity Pathway
Analysis (IPA) software that enables predictions of activation or inhibition of transcription
regulators as well as disease and metabolic functions to be made that is based on expression of
downstream molecules in the dataset as well as relationships of molecules reported in the
database of the IPA program. In this study, we compare and contrast the results obtained for
short (8 weeks) and long (16 weeks) term feeding of the diet on functions and upstream
regulators. We have focused on two main functions: inflammatory response and lipid
metabolism. In inflammatory response, predicted to be inhibited in SPI feeding, we discussed
the role of the superfamily of cytokines interleukin 1 (IL-1) in the development of NAFLD and
how its inhibition could be contributing to the amelioration of liver steatosis. On the side of lipid
metabolism, predicted to be activated in SPI feeding, we discussed the probable role of two
controversial or still not well understood upstream regulators in relation to the development of
NAFLD: TRIM24 and PKD1.
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5.2. Introduction
Obesity is simply defined by extra-accumulation of fat in adipose tissues du to either
excess of calory intake, reduce energy expenditure, or both. According to the Centers for
Disease Control and Prevention (CDC), the prevalence of adults with obesity in the United
States for the period 2017-2018 was of 42.4%; and it has tripled in the last 30 years. For these
reasons it is considered and epidemic and an increasing public health issue (Kincaid, Nagpal,
and Yadav 2020). Obesity is usually associated with insulin resistance, high content of
cholesterol and triglycerides in blood, cardiovascular disease, diabetes type 2, and fatty liver
disease (Niederreiter and Tilg 2018). Nonalcoholic fatty liver disease (NAFLD) is a liver
condition in which the accumulation of lipids in the hepatocytes, and the consequent
inflammation, cannot be explained by alcohol consumption (Castaño-Rodríguez et al., 2017;
Moschen et al., 2013). The complete disorder progresses through a series of stages starting
with the aggregation of lipids in the liver tissue or steatosis. Once the inflammation progresses
and fibrosis appear the next stage is called nonalcoholic steatohepatitis (NASH), that ultimately
leads to cirrhosis; 20% of these cases progresses towards hepatocarcinoma (HCC) (CastañoRodríguez et al. 2017; Moschen et al. 2013). The development of NAFLD is considered to be
the result of complex and not well understood interactions between environmental and genetic
factors, including the immune system and the gastrointestinal microbiome (Niederreiter and Tilg
2018).
There is evidence that dietary components, such as isoflavones and resveratrol, that can
alleviate the symptoms of metabolic conditions such as liver steatosis (Chen et al., 2015).
Resveratrol is a natural polyphenol found in grapes, peanuts, berries, and red wine. Currently,
resveratrol is used as a dietary supplement. Resveratrol can regulate liver lipid metabolism to
prevent the development of NAFLD in animals (Mukherjee, 2010). Another diet component,
genistein is one of the most abundant isoflavones in soybean. It has been found that at the
cellular level genistein inhibits cellular cholesterol synthesis and cholesterol esterification in
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HepG2 human hepatoma cells (Borradaile et al, 2002). Genistein also affects fatty acid
oxidation. It exerts antidiabetic and hypolipidemic effects through the upregulation of the PPARregulated (peroxisome proliferator-activated receptor) gene expression. Thus, the effects of
genistein on cholesterol synthesis and fatty acid oxidation are well known. However, the effect
of genistein on fatty acid synthesis has not yet been identified (Shin et al. 2007). Genistein has
also been reported to enhance adipogenesis through modification of peroxisome proliferatoractivated receptor-γ (PPARγ) (Relic et al. 2009) and canonical Wnt/β-catenin signaling (Su and
Simmen 2009). Genistein could be controlling gene expression through DNA methylation
(Johnson et al. 2012).
A soy protein isolate (SPI)-based diet was shown to attenuate liver steatosis in obese
Zucker rats that was not due to increased arginine intake afforded by the soy protein isolate
intake (Hakkak et al. 2015). Global gene expression analysis of liver has revealed insight into
mechanisms by which SPI-based diet attenuated liver steatosis based on the most differentially
expressed genes (up- and down-regulated) between SPI- and casein (CAS)-based diets
(Kozaczek et al., 2019 [Chapter 3]) and upstream regulators and functions (Chapter 4) after 8
weeks of feeding the respective diets. The purpose of this study was to assess the effects of
short-term (8 weeks) vs long-term (16 weeks) of feeding SPI- or CAS-based diets on the
progression of NAFLD-related gene expression in this obese Zucker rat model.
5.3. Materials and Methods
Animal codes were authorized by the Institutional Animal Care and Use Committee at
the University of Arkansas for Medical Sciences (Protocol code number 3242; approved on
12/6/2011). Liver tissue was obtained from male obese Zucker rats from a previous study
(Hakkak et al. 2015). 6 weeks old obese Zucker rats were purchased from Harlan Laboratories
(Indianapolis, IN). After one week of acclimation, rats were randomly assigned to either a casein
(CAS) diet or soy protein isolate (SPI) diet. They were housed in individual cages and provided
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the diets ad libitum for 16 weeks and all rats were humanely killed, and liver samples obtained,
and flash frozen in liquid nitrogen and stored at −80°C.
A phenol-chloroform solution was used to extract RNA from liver samples. A 1% agarose
gel was used to evaluate the quality of RNA and concentrations were assessed with Take 3
micro volume plate with a Synergy HT multi-mode microplate reader (BioTek, Winooski, VT).
RNA sequencing (RNAseq) of RNA samples was conducted using an Illumina HiSeq 100 base
pair paired end read at the Research Support Facility (Michigan State University, East Lansing,
MI). The CLC Genomics Workbench 8 software that incorporates the pipeline recommended by
Mortazavi et al. (2008) was used to map the reads to Rattus rattus genome assembly (version
4). The RPM data was transformed using log2 to stabilize the variance and then performed a
further quantile normalization. Over 1200 transcripts were differentially expressed (> 1.3 fold
difference and P < 0.05). Ingenuity Pathway Analysis (IPA) commercial software (Qiagen, CA)
was used to help in the interpretation of the dataset.
The analysis of the mRNA expression data was assessed with the software Graph Pad
Prism version 6.00 for Windows, La Jolla California USA, and Student’s t-test. Differences were
considered significant at P<0.05. Ingenuity Pathway Analysis software (Qiagen, CA) was used
in the analysis of global gene expression data. This analysis includes predictions of activation or
inhibition of upstream regulators and functions based on prior knowledge of expected effects
between transcriptional regulators and their target genes from published citations stored in the
IPA program. If the observed direction of change is mostly consistent with either activation or
inhibition of the transcriptional regulator, then a prediction is made, and an activation z score
generated that is also based on literature-derived regulation direction (i.e. “activating” or
“inhibiting”). Activation z scores > 2.0 indicate that a molecule is activated whereas activation z
scores of < -2.0 indicate that a target molecule is inhibited. The p-value of overlap measures
whether there is a statistically significant overlap between the dataset molecules and those

103

regulated by an upstream regulator is calculated using Fisher’s Exact Test, and significance is
attributed to p-values < 0.05.
5.4. Results and Discussion
NAFLD has become a major public health issue worldwide. In this condition, the first
signs are a detrimental aggregation of lipids within the liver cells and inflammation causing
steatosis which can later develops fibrosis and NASH, to finally lead to cirrhosis and HCC (Fang
et al. 2018). In this study, we compared the effects of short (8 weeks) and long-term (16 weeks)
of feeding a SPI-diet that attenuated liver steatosis compared to rats fed a CAS-diet (Hakkak et
al. 2015) on targeted gene expression, functions (inflammatory processes and lipid
metabolism), and upstream regulators in liver from Obese Zucker rats rat model.
Previously, we presented the results of feeding SPI- and CAS-based diets for 8 weeks
on targeted gene expression obtained by RNAseq and PCR in obese Zucker rats (Kozaczek et
al. 2019). Only three out of 12 most differentially genes, NPTX2, IL33 and PRSS8, were still
present among the most differentially expressed genes at 16 weeks in the RNA-seq dataset that
were present at 8 weeks. The top genes that were differentially expressed at both 8 and 16
weeks are shown in Table 1. Only one gene (LCN2) exhibited a change from down regulation at
8 weeks to upregulation at 16 weeks in the SPI-diet group; the remaining genes exhibited
similar direction of differential expression at both 8 and 16 weeks. The discussion of the roles
these genes may play in liver steatosis is provided in Kozaczek et al. (2019, Chapter 3) and in
Chapter 4 of this dissertation and will not be repeated here.
We observed an enhancement of the lipid metabolism and an expansion of decreased
inflammatory response in SPI-diet in the liver going from 8 weeks to 16 weeks of consuming the
diet compared to CAS-fed rats (Fig. 1). The longer the rats were treated with SPI the more
beneficial the effects of this diet on the improvement of lipid metabolism, and constraining the
acute inflammatory response observed in this condition (Fig. 1). It is remarkable how at 8 weeks
of SPI diet there were only two functions of lipid metabolism predicted to be activated, while at
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16 weeks of SPI feeding the number of functions involved in lipid metabolism predicted to be
activated increased up to eight. Several functions that were predicted to be activated (e.g. lipid
transport, efflux, and conversion of lipid) in SPI-fed rats are processes that could reduce lipid
accumulation in hepatocytes. Similarly, processes and functions involved in inflammatory
response such as phagocytosis, chemotaxis of neutrophils, and immune response of cells, were
inhibited in SPI-fed rats thus ameliorating NAFLD symptoms. A wide range of molecules were
predicted to be activated or inhibited in liver of obese rats fed an SPI- compared to CAS-based
diet, as well as complete pathways. As discussed below, these predictions point towards
mechanisms by which SPI ameliorates liver steatosis in the long-term and can serve as
hypotheses to be tested in future studies.
The inflammatory response triggered during NAFLD is still not fully understood. Several
key molecules that were predicted to be inhibited in the liver of the SPI-fed rats known to be
closely involved in inflammation are presented in Table 2. We have covered some of these
target molecules or upstream regulators in previous chapters, such us TNF, CSF2 and its
receptor CSF2RB, TNFRSF12A, and LCN2. However, in this chapter we start to see how all
these molecules and intricate pathways are at last intertwined. Moreover, we start to observe
the beneficial consequences of a sustained SPI diet over 16-week time period (Figure 1 and
Table 2).
On the side of inflammation and immune response in the liver, high levels of fatty acids
cause insulin resistance and lipotoxicity, and in addition to other components can promote a
cascade of inflammation (Fang et al. 2018). The primary pro-inflammatory cytokines related with
the development of NAFLD and progression to NASH are interleukin 1 (IL-1) family, tumor
necrosis factor (TNF) and IL-6 (Fang et al. 2018; Niederreiter and Tilg 2018). It is important to
highlight that these three key types of cytokines are also expressed by adipose tissue in the
presence of inflammation (Niederreiter and Tilg 2018). TNF was already discussed in Chapter 4,

105

although such a conspicuous strong immune mediator it is also present in the current Chapter
for a comparison between short and long-term SPI diets (Table 2). TNF was predicted to be
inhibited in SPI feeding at both short and long-term diet, with a z-score value of -4.22 at 8 weeks
and -3.37 for 16 weeks of feeding, respectively. In other words, TNF had a very consistent
inhibition during the entire time on SPI diet, which could account in part for the mitigation of liver
steatosis.
The IL-1 superfamily of cytokines includes a wide repertoire of members, their receptors,
and antagonists. This family includes IL-1A, IL-1B, IL-1R antagonist, IL-18, IL-33, IL-36, IL-37,
IL-38 (Mirea et al. 2018; Tilg et al. 2020), their receptors with simplified nomenclature from IL-R1
to IL-R10, and decoy receptors (Garlanda et al. 2013). IL-1 cytokines are present in almost all
tissues and organs in the body, and as with most cytokines, they are described as having
pleiotropic biological functions (Tilg et al. 2020; Garlanda et al. 2013). Decoy receptors evolved
as a way to tightly control the devastating inflammatory reactions IL-1 can exert upon their
target site (Garlanda et al. 2013). Some of these cytokines are pro-inflammatory, but some
others can behave as anti-inflammatories (Tilg et al. 2016). IL-33 was discussed in Chapter 3,
as an important “alarmin” of the body’s immune response. Some of the other IL-1 type of
cytokines will be discussed below. IL-1A and IL-1B were predicted to be inhibited in SPI treated
rats, with z-scores values of -2.59 at 8 weeks and -2.25 at 16 weeks for IL-A, and -3.53 at 8
weeks and -2.32 at 16 weeks for IL-B, respectively (Table 2).
Whereas IL-1A is released in an active form from already damaged necrotic and
apoptotic hepatocytes, IL-1B is released in a pro-active form that requires further activation
(Mirea et al. 2018). IL-1A promotes the activation of a cytokines cascade conducing to sterile
inflammation, such as in NAFLD, which is inflammation without external mediators such as
bacteria and endotoxins (Tilg et al. 2016). IL-1B needs to be activated via interaction with
inflammasomes. Inflammasomes are multiprotein complexes constituted by caspases and
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elements acquired from injured cells and microbes (Buzzetti et al. 2016). Once the pro-IL-1B is
cleaved by caspases within the inflammasome it is finally in its active form. IL-1B stimulates the
aggregation of triglycerides in the hepatocytes and formation of lipid droplets. In addition, IL-1B
promotes the production of IL-6 (predicted to be inhibited in this study at 8 weeks, z-score = 2.34, Table 2), another pro-inflammatory cytokine closely involved in the development of NAFLD
and NASH simultaneously with TNF (Mirea et al. 2018). It has been reported that IL-1B can
suppress the expression of IL-33 during intestinal helminth infection (Zaiss et al. 2013). An
important difference between IL-1A and IL-1B is their cellular location. While IL-1A is usually
localized in the nucleus acting as a transcription factor, IL-1B is mainly located in the cytosol
(Garlanda et al. 2013). The type of death of a hepatocyte also influences the type of immune
response IL-1A will trigger. During necrosis, IL-1A is released to the medium and unleashes a
neutrophilic inflammation; in an apoptotic cell the IL-1A remains chromatin-bound and it is not
available for the same inflammation pathway (Garlanda et al. 2013). It appears that SPI may
attenuate liver steatosis by inhibiting IL-1A and IL-1B.
IL-18 is predicted to be inhibited at 8 weeks, z-score -2,19, but not in rats receiving the
SPI diet for 16 weeks (Table 2). Although IL-18 is also activated by the inflammasome and has
also been studied in relation with metabolic disorders and NAFLD, the results in animal models
compared to those in humans are inconsistent (Mirea et al. 2018). Mice with IL-18 deficiency
presented signs of metabolic syndrome, such as dyspilidemia, and insulin resistance, that
suggests there may be a protective role of this cytokine against NAFLD (Netea et al. 2006;
Yamanishi et al. 2016). However, studies in humans have correlated high plasma levels of IL-18
with insulin resistance, type 2 diabetes and atherosclerosis suggesting that IL-18 could be
involved in the progression of metabolic disorders (Hung et al. 2005; Trøseid et al. 2010). The
predicted inhibition of IL-18 by SPI diet in our study suggests similarities with the mouse studies
(Netea et al. 2006; Yamanishi et al. 2016) but not those in humans (Hung et al. 2005; Trøseid et
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al. 2010). Further research on IL-1A and B and its role in liver steatosis and NAFLD is
warranted.
Upstream regulators related with the improvement of lipid metabolism in SPI feeding
such as Acyl-CoA oxidase 1 (ACOX1) and the transcription factors Hepatocyte nuclear factor 1
and 4 alpha (HNF1A and HNF4A, respectively) were discussed in Chapter 4. Here we can
follow these genes in both short and long-term diet with SPI (Table 3). ACOX1 was predicted to
be active at 8 weeks (z-score = 3.12) and at 16 weeks (z-score = 4.04). HNF1A was activated at
both 8 and 16 weeks (z-scores = 2.24 and 2.55). Interestingly, HNF4A was only predicted to be
active at 16 weeks of SPI feeding (z-score = 3.44). Since both transcription factors regulate the
expression of the other, it is not clear why HNF4A was not predicted to be activated after 8
weeks in the present study.
Tripartite Motif Containing 24 (TRIM24) regulates gene expression by binding to the
activation function 2 (AF2) region of several nuclear factors such as estrogen, retinoic acid, and
vitamin D3 receptors (Charrez et al. 2016). TRIM24 is predicted to be activated at 8 and 16
weeks with z-scores values of 2.63 and 2.12, respectively (Table 3). Similar to findings on IL-1A
and 1B above, there are discrepancies in studies of this TRIM24 in animal models compared to
those in humans. In murine models the deficiency or lack of TRIM24 is associated with the
decrease in expression of genes involved in oxidation and reduction, lipid and steroid
metabolism, and the increase of genes involved in endoplasmic reticulum stress as well as cell
cycle pathways; all of which are characteristics associated with NAFLD (Gu et al. 2016). Its
normal expression is linked to the repression of lipid accumulation in liver cells (Jiang et al.
2015). The complete loss of function of TRIM24 can drive the progression of NAFLD to NASH to
HCC (Jiang et al. 2015). Conversely, in humans the expression of TRIM24 is associated with
the development of different types of cancer, including HCC (Freese et al. 2019). Our study
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concurs with previous studies base on mice and rat models, since TRIM24 seems to be helping
with the reduction of liver steatosis in animals consuming the SPI-based diet.
Polycystin 1 (PKD1), jointly with PKD2, is part of a receptor ion channel complex that
when mutated causes polycistic kidney disease (Menezes et al. 2016; Roy and Marin 2018).
PKD1 was predicted to be activated at 8 weeks with z-score of 2.40, and at 16 weeks with a zscore of 2.89, respectively (Table 3). PKD1 has been extensively studied and linked with
polycystic kidney disease and polycystic liver disease (Cnossen and Drenth 2014; Roy and
Marin 2018). However, to our knowledge only one study has associated this molecule with
NAFLD (Rada et al. 2018).
In summary, it is apparent that feeding a SPI-based diet to a genetically obese male rat
model that reduced liver steatosis resulted in predicted reductions (based on expression of
genes in the dataset and literature citations in the pathway analysis database) in inflammatory
mechanisms while enhancing lipid transport out of the liver. Around each of the upstream
regulators that are presented in the Tables 2 and 3 predicted to be activated or inhibited in this
transcriptomic dataset, hypotheses can be generated and tested in future studies to help
develop treatments that can alleviate liver steatosis and hopefully slow the progression of
NAFLD to NASH and cirrhosis.
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5. 5 Tables and Figures
Table 1. Top differentially expressed genes that up and down-regulated (out of the top 10) that
were differentially expressed at both 8 and 16 weeks in rats fed the SPI-diet compared to those
fed the CAS-diet. Mean values (n=8)
Fold Diff
RNAseq
Genes

8
weeks

16
weeks

NPTX2
GPT
INMT
HAL
Serpina6
IL33
PRSS8
Ajuba
CSF2RB
CYP2C12
LCN2
TNFRSF12A

1.88
2.02
1.83
1.85
1.51
1.52
-5.71
-2.65
-1.46
-2.45
-2.45
-2.3

3.8
1.60
1.5
1.95
1.36
2.32
-3.09
-2.81
-2.69
-2.3
1.39
-1.81
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Table 2. Comparison of Upstream regulators predicted to be inhibited after 8 and 16 weeks of SPI feeding (short and long-term diet). The numbers between the 8 and 16 week
upstream regulator predictions show the coincidence of predicted inhibition of genes (in rank order of inhibition for 8 vs 16 weeks and 16 vs 8 weeks. (An ‘x’ indicates that the
prediction was not provided at 16 weeks, and a ‘y’ indicates that the prediction was not provided at 8 weeks). Activation Z-scores all had a P value of overlap (Fisher’s exact ttest) of P < 0.01.
8 weeks

16 weeks

cytokine
cytokine
cytokine

-4.94
-4.22
-3.53

8 vs
16
wk
1-2
2-1
3-14

other

-3.51

4-8

4-6

4. PRL

complex

-3.22

5-11

5-y

5. ERBB2

cytokine

-3.22

6-4

6-

6. Pkc(s)

transporter

-3.06

7-x

7-31

7. MKNK1

Inhibitor of nuclear
factor kappa-B kinase

kinase

-2.97

8-x

8-4

8. MYD88

9. TICAM1

Protein Inducing
Interferon Beta

other

-2.84

9-x

9-20

9. VEGFA

10. RETNLB

Resistin-like beta

other

-2.83

1026

10-x

10.TP53

Toll-like receptor 4

transmembrane
receptor

-2.78

11-x

11-5

11.
NFkB

kinase

-2.74

12-x

12-y

12. SYVN1

complex

-2.65

13-x

13-y

growth factor

-2.65

14-x

14-3

other

-2.62

15-

Protein Kinase C

group

-2.61

16-

MAPK group

group

-2.61

17-3

kinase

-2.59

18-x

18-y

cytokine

-2.59

1917

growth factor

-2.48

20-9

Upstream
Regulator
1. IFNG
2. TNF
3. IL1B
4. MYD88
5. NFkB
(complex)
6. PRL
7. UCP1
8. CHUK

11. TLR4
12. IKBKB
13. CG
14. FGF2
15. CD44
16. Pkc(s)
17. ERK
18. EGFR
19. IL1A
20. VEGFA

Name
Interferon gamma
Tumor necrosis factor
Interleukin 1 beta
Myeloid differentiation
primary response 88
Nuclear factor kappa
enhancer of B cells
Prolactin
Uncoupling Protein 1
(Thermogenin)

Inhibitor of Nuclear
Factor Kappa B Kinase
beta
Vitamin D Binding
Protein
Fibroblast Growth
Factor 2
Phagocytic
Glycoprotein 1

Epidermal growth
factor receptor
Interleukin 1 alpha
(hematopoietin 1)
Vascular endothelial
growth factor A

Molecule Type
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Activation zscore

16 vs
8 wk
1-2
2-1
3-17

Upstream
Regulator

Tumor necrosis factor
Interferon Gamma
MAPK group
Prolactin (member
growth hormone)
Member epidermal
growth factor receptor
Protein Kinase C
MAPK interacting kinase
1
MYD88 innate immune
signal transducer
adaptor
Vascular endothelial
growth factor A

Molecule Type

Activation zscore

Cytokine
Cytokine
Group

-3.37
-3.30
-3.11

Cytokine

-2.77

Kinase

-2.76

Group

-2.68

Kinase

-2.65

Other

-2.57

growth factor

-2.48

Tumor protein p53

transcription
regulator

-2.42

Nuclear Factor kappa B

Complex

-2.37

Synoviolin 1

Transporter

-2.33

13. RAC1

RAC family small
GTPase

enzyme

-2.32

14. IL1B

Interleukin 1 beta

cytokine

-2.32

15. CSF2

Colony Stimulating
Factor 2

cytokine

-2.29

16. Jnk

Jnk dimer

group

-2.28

17. IL1A

Interleukin 1 A

cytokine

-2.25

18. TGM2

Transglutaminase 2

enzyme

-2.24

1915

19. CD44

CD44 molecule

other

-2.24

20-y

20. LTBR

Lymphotoxin beta
receptor

transmembrane
receptor

-2.24

1522
1627
1719

1. TNF
2. IFNG
3. ERK

Name

21. ERK1/2
22. CSF2

Mitogen-Activated
Protein Kinase 3
Colony Stimulating
Factor 2

group

-2.43

21-x

21-y

21. PLG

Plasminogen

peptidase

-2.22

cytokine

-2.43

2215

22-y

22. GLI1

GLI family zinc finger 1

transcription
regulator

-2.22

kinase

-2.20

growth factor

-2.19

transcription
regulator

-2.18

Restin like beta

other

-2.14

Interleukin 5

cytokine

-2.02

complex
transmembrane
receptor

-2.00

23. GNA12

G Protein Subunit
Alpha 12

enzyme

-2.41

23-x

23-

23. MAP3K1

24. CD38

Cyclic ADP-Ribose
Hydrolase 1

enzyme

-2.41

24-x

24-y

24. FGF19

25.
IRF3

Interferon regulatory
factor 3

transcription
regulator

-2.36

25-x

25-y

25. EZH2

P38 MAP Kinase

group

-2.35

26-x

2610

26. RETNLB

Jnk dimer group

group

-2.35

27-y

27. IL5

Interleukin 6

cytokine

-2.34

2716
28-x

28. Pka

Interleukin 4

cytokine

-2.31

29-x

28-y
2930

Tumor necrosis factor
receptor 1 beta

transmembrane
receptor

-2.24

3029

30-y

31. MKNK1

MAPK interacting
kinase 1

kinase

-2.24

31-x

31-y

32. TLR7

Toll-like receptor 7

transmembrane
receptor

-2.22

32-x

32-y

kinase

-2.22

33-x

transcription
regulator

-2.22

34-x

-2.21

35-x

-2.20
-2.19

36-x
37-x

-2.18

38-x

group

-2.13

39-x

transcription
regulator

-2.03

40-x

transcription
regulator

-2.00

41-x

other

-2.00

42-x

26.
P38 MAPK
27.
Jnk
28. IL6
29. IL4
30. TNFRSF1B

33. PRKCE
34. CREB1
35. IRF7
36. F7
37. IL18
38. SIRT1
39. Ifnar
40. STAT1
41. EGR1
42. HRG

Protein kinase C
epsilon
Cyclic AMPResponsive ElementBinding Protein 1
Interferon regulatory
factor 7
Coagulation Factor VII
Interleukin 18
Sirtuin 1
Interferon Alpha/Beta
Receptor
Signal transducer and
activator of
transcription 1
Early Growth
Response 1
Histidine Rich
Glycoprotein

transcription
regulator
peptidase
cytokine
transcription
regulator
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Mitogen activated
protein kinase kinase
kinase 1
Fibroblast growth factor
19
Enhancer of zeste 2
polycomb repressive
complex 2

Protein kinase alpha
Tumor necrosis factor
29. TNFRSF1B
receptor 1 beta
Protein phosphatase 1
30. PPP1R13L regulatory subunit 13
like
RUNX family
31. RUNX2
transcription factor 2
32. CNR1

Cannaboid Receptor 1

transcription
regulator
transcription
regulator
G-protein coupled
receptor

-2.00
-2.00
-2.00
-2.00

Table 3. Comparison of Upstream regulators predicted to be activated after 8 and 16 weeks of SPI diet (short and long-term feeding). The numbers between the 8- and 16-week
upstream regulator predictions show the coincidence of predicted inhibition of genes (in rank order of inhibition for 8 vs 16 weeks and 16 vs 8 weeks. (An ‘x’ indicates that the
prediction was not provided at 16 weeks, and a ‘y’ indicates that the prediction was not provided at 8 weeks). All activation Z-scores had a P value of overlap (Fisher exact t-test)
of P < 0.001.
8 weeks
Upstream
Regulator
1. ACOX1
2.
α catenin
3.
IgG
4.
VCAN
5.
INSIG1
6.
TRIM24
7.
COL18A1
8.
HOXD10
9.
PKD1
10.
IL1RN
11.
mir-21
12.
IL10RA
13.
HNF1A
14.
ZBTB20
15.
IGHM
16.
CFTR
17.
PSEN1
18.
APOE

16 weeks

Name

Molecule Type

Activation
z-score

8 vs 16 vs
16 wk 8 wk

Acyl-CoA oxidase 1

enzyme

3.12

1-1

1-1

Alpha catenin

group

2.87

2-9

2-y

Immunoglobulin G

complex

2.71

3-10

3-9

other

2.65

4-x

4-5

Insulin induced gene 1

other

2.65

5-4

5-y

Tripartite motif containing 24

transcription
regulator

2.63

6-x

6-13

Endostatin

other

2.45

7-x

7-y

Homeobox D10

transcription
regulator

2.45

8-x

8-y

Polycystin-1

ion channel

2.40

9-3

9-2

Interleukin 1 Receptor
Antagonist

cytokine

2.36

10-x

10-3

MicroRNA 21

microRNA

2.31

11-x

11-y

Interleukin 10 Receptor
Alpha
Hepatocyte nuclear factor 1
homeobox A
Zinc Finger and BTB
Domain Containing 20
Immunoglobulin Heavy
Constant Mu
Cystic Fibrosis
Transmembrane
Conductance Regulator

transmembrane
receptor
transcription
regulator
transcription
regulator
transmembrane
receptor

2.27

12-x

12-6

2.24

13-6

1319

2.24

14-x

14-y

2.21

15-x

15-y

ion channel

2.21

16-x

Presenilin 1

peptidase

2.18

17-x

Apolipoprotein E

transporter

2.12

18-x

Versican
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Upstream
Regulator
1.
ACOX1
2.
HNF4A
3.
PKD1
4.
INSIG1
5.
SNAI1
6.
HNF1A
7.
ABCB6
8.
ABCB4
9.
α catenin
10.
IgG
11.
AHR
12.
TRIM24
13.
ZNF106
14.
GPS2
15.
SAFB

Name

Molecule Type

Activation
z-score

Acyl-CoA oxidase 1

enzyme

4.04

Hepatocyte nuclear
factor 4 alpha

transcription
regulator

3.44

Polycystin-1

ion channel

2.89

Insulin induced gene 1

other

2.71

transcription
regulator

2.56

transcription
regulator

2.55

transporter

2.39

transporter

2.22

Alpha catenin

group

2.18

Immunoglobulin G

complex

2.17

Aryl hydrocarbon
receptor
Tripartite motif
containing 24

ligand-dependent
nuclear receptor
transcription
regulator

Zinc finger protein 106

other

2.00

G protein pathway
suppressor 2
Scaffold attachment
factor beta

transcription
regulator

2.00

other

2.00

Snail family
transcriptional repressor
1
Hepatocyte nuclear
factor 1 homeobox A
ATP binding cassette
subfamily B member 6
ATP binding cassette
subfamily B member 4

2.15
2.12

19.
ZNF106
20.
ACKR2
21.
PRDM1
22.
CHD4
23. Mt2
24. Irgm1
25. Mt1

Zinc finger protein 106

other

Atypical Chemokine
Receptor 2

G-protein coupled
receptor
transcription
regulator

PR Domain Zinc Finger 1

2.00

19-13

2.00

20-x

2.00

21-x

Chromodomain-helicaseDNA-binding protein 4

enzyme

2.00

Metallothionein-2

other

2.00

Immunity Related GTPase
M

other

2.00

Metallothionein-1A

other

2.00
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22-x
23-x
24-x
25-x
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Figure 1. Comparison of Diseases and Functions related with Lipid metabolism predicted to be activated (orange) and Inflammatory
response predicted to be inhibited (blue) at 8 and 16 weeks of SPI feeding. The number of functions inhibited and activated
increased in the long-term SPI diet.

CONCLUSION
In summary, we believe that the global gene expression analysis conducted in this
study on liver tissue obtained by Hakkak et al. (2015) from genetically obese Zucker
rats fed a diet containing Soy Protein Isolate versus Casein for 8 and 16 weeks (shortand long-term, respectively) has helped to gain some insight on the overall onset of
non-alcoholic fatty liver disease and its interaction with diet components. In addition, we
consider that the validation of the transcriptomic data was satisfactory, and that targeted
gene expression has helped to understand the effects of different dietary protein
sources (soy protein isolate versus a casein-based diet) on various cellular
mechanisms. Furthermore, the soy protein isolate appears to reduce the expression of
proinflammatory molecules/processes and to enhance lipid transport, mostly in the longterm, although can also be observed at 8 weeks. Conversely, casein seems to increase
inflammatory processes, which concurs with evidence in literature. The upstream
regulator analysis conducted with the commercial software program used in
interpretation of the transcriptomic data has revealed potential insight into mechanistic
networks associated with feeding soy protein isolate and casein based diets that
requires further research to clearly elucidate these mechanisms. We consider that the
results from this study can help not only in understanding the development of liver
steatosis in obese animals, but also possibly lead to interventions that can help to
prevent development of non-alcoholic steatohepatitis and irreversible damage to liver in
the form of cirrhosis and development of hepatocellular carcinoma.
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